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The human vitamin D receptor (hVDR) is a member of the nuclear receptor 
superfamily, involved in calcium and phosphate homeostasis; hence implicated in a 
number of diseases, such as rickets and osteoporosis.  This receptor binds 1α,25-
dihydroxyvitamin D3 (also referred to as 1,25(OH)2D3) and other known ligands, such as 
lithocholic acid.  Specific interactions between the receptor and ligand are crucial for the 
function and activation of this receptor, as implied by the single point mutation, H305Q, 
causing symptoms of Type II rickets.  In this work, further understanding of the 
significant and essential interactions between the ligand and the receptor were 
deciphered, through a combination of rational and random mutagenesis.  A hVDR 
mutant, H305F, was engineered with increased sensitivity towards lithocholic acid, with 
an EC50 value of 10 µM and 40 + 14 fold activation in mammalian cell assays, while 
maintaining wild-type activity with 1,25(OH)2D3.  Furthermore, via random mutagenesis, 
H305F/H397Y was discovered to bind cholecalciferol, a precursor in the 1α,25-
dihydroxyvitamin D3 biosynthetic pathway, which does not activate wild-type hVDR.  
The variant H305F/H397Y is activated by cholecalciferol concentrations as low as 100 
nM, with an EC50 value of 300 nM and 70 + 11 fold activation in mammalian cell assays.  
In silico docking analysis of the variant displays a dramatic conformational shift of 
cholecalciferol in the ligand binding pocket in comparison to the docked analysis of 
cholecalciferol with wild-type hVDR.  This shift is hypothesized to be due to the 
introduction of two bulkier residues, suggesting that the addition of these bulkier residues 
 xviii 













1.1 Nuclear Receptor Superfamily 
Nuclear receptors (NRs) are ligand-activated transcription factors.  Upon ligand 
binding, these receptors activate the transcription of essential genes required for a number 
of cellular and physiological processes including proliferation, differentiation, and 
development [1-4]. For example, the human vitamin D receptor controls the transcription 
of genes involved in calcium and phosphate homeostasis [5].  Also, the pregnane X 
receptor is involved in upregulating the expression of genes that are involved in 
detoxification of the body [6].  Due to their involvement in gene expression throughout 
mammalian systems, NRs are implicated in a number of diseases including, cancer, 
diabetes, and osteoporosis [5, 7-10].  
To date, there are 48 known human nuclear receptors [8].  NRs fall into three 
subfamilies:  steroid receptors, such as estrogen receptor; non-steroidal receptors, such as 
retinoid X receptor; and orphan receptors, such as liver receptor homolog-1 [7, 8, 11-14].  
Steroid receptor ligands include estrogen and testoterone; whereas non-steroidal receptors 
can bind steroid-like ligands or other molecules, such as fatty acids or lipids [2, 8, 13].  
The orphan receptors are a subfamily of nuclear receptors whose wild-type ligand is 
unknown, such as steroidogenic factor-1 [15].  These receptors bind a wide variety of 
ligands due to the differences in their ligand binding pockets [8]. 
1.2 Nuclear Receptor Structure 
NRs consist of five to six domains, labeled A to F: a N-terminal domain (A/B), a 
DNA binding domain (DBD) (C), a hinge region (D), a ligand binding domain (LBD) 
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(E), and a C-terminal domain (F) (Figure 1.1) [1, 2, 11, 16, 17].  Each of these domains 
plays a role in the structure and function of NRs.  The A/B region consists of the N-
terminal portion of the protein and contains the activation function-1 (AF-1) domain.  
This domain is highly disordered and the sequence of this domain varies, lacking 
conservation among the members of the superfamily [7, 18, 19].   The AF-1 domain is 
capable of functioning independently.  For example, transcriptional activation has been 
shown to occur with the estrogen receptor AF-1 domain in the presence of tamoxifen [7, 
18-20].  The AF-1 domain has also been shown to be the target of post-translational 
modifications and to interact indirectly with transcriptional machinery [20, 21].  Similar 
to the A/B domain, the F domain is also not well characterized, but this domain has been 
implicated in ligand binding and nuclear receptor dimerization [11]. 
The DBD binds to short specific sequences of DNA known as hormone response 
elements (HRE), and is the most conserved domain among NRs, sharing approximately 
95% sequence identity among members of the superfamily [1, 4, 7, 8, 13, 19].  
Crystallographic studies have shown that the DBD is predominately α-helical and 
consists of two cysteine-rich zinc finger motifs.  Each zinc finger contains four cysteines 
coordinated to one zinc ion, allowing the α-helices to bind to specific base pairs in the 
major groove of the DNA [11, 22, 23].  The DBD is divided into subdomains known as 
the P and D boxes (Figure 1.2) [24].  These regions have been shown to determine HRE 
specificity, define the DBD dimerization interface, and make contacts with the flanking 
















































































specificity and spacing, respectively [11, 26, 27].  HREs can be located upstream or 
downstream of the target gene, and are oriented as half-sites (direct-, indirect-, or inverted 
repeats).  Direct repeats are homologous sequences of DNA that are separated by a 
number of spacing base pairs; these base pairs are specific to each NR monomer, 
homodimer, or heterodimer (i.e. AGTTCAtgagAGTTCA).  Inverted repeats contain 
complementary sequences separated by a spacer (i.e. GACTGCtgacGCAGTC).  Due to 
the fact that most NRs function as homo- or heterodimers, a half-site is required for each 
partner.  The majority of steroid receptors function as homodimers, which bind to 
inverted repeats, whereas most non-steroidal receptors function as heterodimers and bind 
to direct repeats [11, 28, 29].  
The hinge region, or D domain, conjoins the DBD and LBD.  This domain allows for 
rotation of the DBD, reducing steric hindrance between the two domains [11]. The D 
domain contains a nuclear localization sequence, which is necessary for the translocation 
of NRs into the nucleus where transcription occurs. Some nuclear receptors, such as the 
steroid receptors, bind a ligand in the cytosol, and are then transported into the nucleus to 
interact with the corresponding HRE.  NRs such as the glucocorticoid receptor, androgen 
receptor, estrogen receptor, and progesterone receptor bind ligands prior to translocation 
[1, 7, 11, 30].  Conversely, NRs such as the retinoid X receptor, liver X receptor, 
pregnane X receptor, and the human vitamin D receptor translocate into the nucleus 
without bound ligand [2, 5, 8, 31].  
The LBD plays a role in dimerization, ligand binding, and coregulator interactions 
[19].  The majority of NR LBDs consists of 12 α-helices (H1-H12) and a short β-turn, 
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H3 comprise one of the layers, whereas the H4, H5, the β-turn, H8, and H9 make up the 
central layer of the LBD.  H6, H7, and H10 make up the third layer of the LBD.  Upon  
ligand binding, H3, H5, and H12 undergo a conformational change  [19, 30, 32-34].  One 
of the most critical helices, H12, consists of the activation function-2 (AF-2) domain, 
which plays a critical role in the ligand activation of NRs, through interactions with 
coactivators [19, 30]. 
     While nuclear receptor LBDs share varying degrees of similarity with their overall 
secondary structure content, the differences in their ligand binding pockets (LBP) account 
for the diverse ligand binding profiles of these nuclear receptors [8, 11, 30, 35].  LBP’s 
vary based on size, shape, volume, and chemical properties among various nuclear 
receptors [11, 36].  For example, the pregnane X receptor (PXR) has a pocket volume of 
~1200 Å
3
, while the estrogen receptor (ER) has a pocket volume of ~450 Å
3
 [13, 31].  
The chemical properties or polarity of the LBP also contribute in determining the 
different types of ligands capable of binding the receptors.  Polar or charged residues can 
provide hydrogen bonding interactions between the ligand and the receptor, as observed 
with the hydrogen bonds formed between the 3-hydroxyl group of the “A” ring of 
estradiol and arginine 394 and glutamate 353 of ER.  These hydrogen bonds are crucial 
for stabilizing the ligand in the pocket, leading to activation of the receptor.  The polar 
and charged residues can also form salt bridges between surrounding residues and the 
ligand, as can be observed with the carboxylate of all-trans retinoic acid and arginine 278 
and serine 289 of retinoic acid receptor (RAR) [37].  Hydrophobic residues can provide 
van der Waals interactions between the ligand and receptor, such as that seen with 
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isoleucine 268, alanine 272, and tryptophan 305 of retinoid X receptor, which are known 
to form hydrophobic contacts with 9-cis retinoic acid [1, 2, 8, 11, 12, 30].   
1.3 Nuclear Receptor Function 
As ligand activated transcription factors, NRs function in a precise manner involving 
a series of molecular events that lead to regulation of essential genes [1, 30, 38].  NRs 
generally function as homodimers or as heterodimers with the retinoid X receptor (RXR) 
[1, 11, 39, 40].  Heterodimers are further classified into three categories: permissive, 
conditional, and non-permissive [39].  Permissive partners require the respective ligands 
of both heterodimer partners in order for activation of transcription to occur.  An example 
is seen with the RXR and the pregnane X receptor (PXR), in which case transcriptional 
activation requires both ligands, 9-cis retinoic acid and rifampicin (synthetic/non-natural 
ligand), respectively.  Conditional partners, such as RXR and retinoic acid receptor, 
require only one of the ligands to be present for activation; however, maximal activation 
is achieved if both ligands are present [39].  Finally, non-permissive partners only require 
the ligand of the NR partner and not the heterodimerization partner RXR, as seen in the 
case of vitamin D receptor (VDR) and retinoid X receptor, where only 1α,25-
dihydroxyvitamin D3 is needed for activation of transcription [39].   
As ligand activated transcription factors, NRs are involved in gene repression and 
activation.  These ligands vary in size, shape, and chemical properties, such as rifampicin, 
27-hydroxycholesterol, and estradiol [2, 13, 41, 42].  Most nuclear receptors must bind a 
ligand (agonist) for transcription to occur and very few are considered to be constitutively 
active, or activated without the presence of a bound ligand.  NRs are also capable of 
binding other ligands (antagonists or inverse agonists) that lead to repression of 
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transcription [1, 11].  Most antagonists function by displacing the agonist from the ligand 
binding pocket, while inverse agonists function by binding to receptors that express 
constitutively or have high basal activity, repressing transcriptional activation [43-45].   
Repression of transcription via NRs can occur one of three ways.  In the structure of 
an apo NR, the AF-2 domain is positioned away from the receptor, exposing the 
corepressor binding site on the LBD, allowing corepressors to bind.  Common human 
corepressors include the nuclear receptor corepressor (NCoR) and silencing mediator for 
retinoid and thyroid hormone receptors (SMRT), each of which binds to a specific 
hydrophobic groove on the NR LBD, through the CoR box that contains a 
LXXXIXXXI/L motif [46-50].  The binding of the corepressor induces the recruitment of 
transcriptional complexes, including histone deacetylases (HDACs) [51].  HDACs 
deacetylate lysine residues in the N-terminal tail of histone complexes, leading to a more 
tightly packed chromatin structure and preventing RNA polymerase from initiating 
transcription (Figure 1.4A) [43, 44, 51, 52].   
Agonist binding causes structural changes throughout the receptor, particularly in H3, 
H5, and H12.  The most notable change occurs in H12, where the AF-2 domain is 
rearranged, positioning H12 closer to the LBD, and serving as a seal to the LBP (Figure 
1.5) [53].  The conformational change leads to the creation of a hydrophobic groove 
between H3, H5, and H12, for coactivator (CoAc) binding [54-57].  CoAcs contain 
multiple LXXLL motifs, collectively known as the LXXLL NR box, which bind to the 
nuclear receptor in the hydrophobic groove.  The binding of these proteins leads to the 























































































































































































































































































































































































































































































































































































HATs acetylate the lysine residues on the N-terminal tail of histones leading to a less 
compact histone complex, allowing RNA polymerase to access the DNA and initiate 
transcription  (Figure 1.4B) [55, 58-60]. 
Due to their implications in a number of diseases and their involvement in 
transcriptional activation and repression, the development of new drugs for nuclear 
receptor based diseases is of vast interest to pharmaceutical companies.  To date, 
approximately 10% of the most commonly prescribed drugs on the market are NR 
ligands [7, 8].  Some of these drugs include: peroxisome proliferator-activated receptor 
ligands, such as thiazolidiones, used to treat Type II Diabetes.  One of the most 
commonly known drugs that binds a nuclear receptor is tamoxifen, an estrogen receptor 
antagonist, used to treat breast cancer [9, 10].  To discover new drugs for NRs, 
understanding of the structure/function relationship between nuclear receptors and their 
various ligands is critical. 
1.4 Human Vitamin D Receptor 
The human vitamin D receptor (hVDR) is a nuclear receptor primarily involved in 
biological processes such as apoptosis, immune responses, and calcium and phosphate 
homeostasis [61].  hVDR was first cloned from the human intestine in 1988 and since 
that time, 11 orthologs have been discovered [62-68].  Each VDR ortholog binds the 
same natural ligand, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) [62-69].  In addition to 
1,25(OH)2D3, VDR is known to bind a variety of 1,25(OH)2D3 analogs and bile acids, 
such as lithocholic acid (LCA), which displays an EC50 value of 12 µM in comparison to 
an EC50 value of 1 nM for hVDR and 1,25(OH)2D3  (Figure 1.6) [12, 70-74].   
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hVDR is a nuclear receptor comprised of 427 amino acids [62].  The ligand binding 
domain of this receptor is comprised of 303 amino acids with a ligand binding pocket 
volume of 693 Å
3
.  The LBP is elongated and consists of polar and charged residues at 
the ends of the pocket, and hydrophobic residues surrounding the pocket interior (Figure 
1.7).  These residues contribute essential molecular interactions between the ligand and 
receptor, such as hydrogen bonding and van der Waals forces, which are required for 
receptor activation and function.  Disruption of these key interactions reduces the activity 
of a functional receptor and in some cases, leads to detrimental effects.  For example, a 
single point mutation in the LBD of hVDR, H305Q, causes a 10-fold decrease in 
sensitivity of the receptor to 1,25(OH)2D3, causing Type II rickets [75, 76].  Vitamin D 
analogs used to treat hVDR-related diseases have higher calcemic effects than 
1,25(OH)2D3.  To design new drugs for the treatment of these diseases, a better  
Figure 1.6:   hVDR ligands. 1α,25-Dihydroxyvitamin D3 and lithocholic acid are 
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 understand the structure/function relationship between hVDR and various ligands is 
needed. 
hVDR is implicated in several diseases, such as osteoporosis, hypocalcemia, 
hyperthyroidism, diabetes, and rickets [5].  Rickets (Type I and Type II), is a disorder 
stemming from a vitamin D deficiency and impared hVDR function [77-79].  This results 
in growth retardation, bone deformities, hypocalcemia, and secondary hyperthyroidism 
[77, 80].  In Type II rickets, mutations in the ligand binding domain of hVDR prevent the 
ability of the natural ligand, 1,25(OH)2D3, from binding to the receptor [77].  However, 
in Type I rickets, the 1α-hydroxylase, responsible for the hydroxylation of 25-
hydroxyvitamin D to its active form, 1,25(OH)2D3, is nonfunctional.  Thus, patients with 
Type I rickets are unable to generate active vitamin D and are treated with 1,25(OH)2D3 
supplements [77, 79, 80].  There is great interest in the design of vitamin D analogs able 
to bind hVDR, which counteract the vitamin D deficiency caused  by Type II rickets [81].  
1,25(OH)2D3 is rapidly broken down by the body; therefore, synthetic analogs, which are 
not broken down as rapidly, are being designed.  These analogs need to also be designed 
with fewer calcemic effects so that their prolonged presence in the body reduces negative 
effects on the pathways in which hVDR is involved [5].  The goal of this work is to 
engineer a hVDR variant that is capable of binding a novel small molecule, 
cholecalciferol.  Through this process, a better understanding of the structure/function 
relationship between hVDR and various ligands will be attained, which will aid in 




Due to the ability of NRs to bind a variety of ligands, their involvement in a number 
of biological processes, and their implication in a number of diseases, nuclear receptors 
make great targets for drug design and protein engineering.  Protein engineering of 
nuclear receptors will allow us to develop a better understanding of structure/function 
relationship between the receptors and ligands.  hVDR makes a good target for protein 
engineering due the lack of structure/function information known about this receptor.  
Also, the knowledge gained via protein engineering will allow for a better understanding 
of this receptor such as which residues are necessary for ligand binding and activation. 
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2.1.1 Human Vitamin D Receptor Background 
Nuclear receptors are potential targets for protein engineering due to their 
involvement in a variety of biological processes and their ability to bind a wide variety of 
ligands.  The diversity in the LBP’s implies that specific combinations of residues are 
necessary for binding specific ligands.  Therefore, a better understanding of the 
structure/function relationship between the receptor and ligand is necessary.  hVDR was 
chosen for protein engineering based on this receptors’ implication in diseases, as well as 
the impact of a single point mutation on the receptor function, as seen with the H305Q 
mutation of hVDR, which leads to Type II rickets [1, 2].  A better understanding of the 
residues that are important in the binding of various ligands, as well as the mutational 
tolerance in hVDR, can be used towards developing new drugs that can be used to treat 
hVDR-related diseases. The development of new drugs is crucial for the treatment of 
hVDR related diseases.  Also, better understanding of the important residues of this 
receptor will aid in further overall knowledge of the structure and function relationship of 
this receptor.  
Previously, structural and mutational studies with hVDR were performed to assess the 
role of residues within the ligand binding pocket important for ligand binding and 
activation [3-12]. Crystal structures of hVDR with 1,25(OH)2D3 and other agonists, such 
as MC1288 and KH1060, as well as mutational analyses, such as alanine scanning, have 
provided useful preliminary information regarding interactions vital to ligand binding.  
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The aforementioned crystal structures maintain the same hydrogen bonding interactions 
with Y143, S237, R274, S278, H305, and H397.  However, the aliphatic chain 
arrangements of the ligands allow for different contacts with the surrounding residues 
including:  L309, L404, and V418.  Hydrogen bonding residues were determined via 
alanine scanning mutagenesis, and residues necessary for activation were identified by 
determining which residue mutations lead to receptor inactivation [9, 12, 13].   
Initially, Y143, S237, R274, S278, H305, and H397 were found to form essential 
hydrogen bonds with 1,25(OH)2D3, and all of these residues except S278 are essential to 
obtain wild-type activation of hVDR with 1,25(OH)2D3 (Figure 2.1) [3, 6-9, 12, 13].  
However, Mizwicki et al. have since shown that the hydrogen bonds between H305, 
H397, and the ligand are unnecessary for activation with 1,25(OH)2D3.  Mutating C288 to 
a glycine or alanine and W286 to phenylalanine or alanine was also shown to inhibit 
transcriptional activation [5, 10, 11, 13].  Previous structural analysis of the hVDR 
residues and the work of Mizwicki et al. has prompted a better understanding regarding 
the mutational tolerance of these residues.  The mutational tolerance of the hVDR LBP 
will allow for a more thorough understanding about crucial residues in ligand binding and 
activation as well as determining residues that are capable of being mutated and maintain 
activation.  Three protein libraries were designed and tested using a method called 
chemical complementation, which links the survival of yeast to the activation of the 














Figure 2.1: Known important residues in the hVDR ligand binding pocket.
For example, Y143 and R274 form hydrogen bonds with the ligand, whereas 
W286 and L233 are known to form hydrophobic contacts with the ligand
Figure 2.1: hVDR ligand bin ing pock t. Known mportant 
residues involved in ligand activation are shown. For example, 
Y143 and R274 form hydrogen bonds hydroxyl groups of the 
ligand, whereas W286 and L233 are known to form hydrophobic 




2.1.2  Chemical Complementation 
Chemical complementation is a three-component system in yeast that links the 
survival of yeast to the function of a nuclear receptor and a small molecule [14-17].  This 
system is comprised of three-components: a Gal4 DNA binding domain (GBD) fused to a 
 nuclear receptor LBD, a nuclear receptor coactivator bound to a Gal4 activation domain 
(GAD), and small molecule.  Gal4 is a ligand independent yeast transcription factor, 
which consists of a DNA binding domain and an activation domain.  The yeast strain 
PJ69-4A is used, which consists of Gal4 response elements controlling the expression of 
selective markers, such as ADE2 and HIS3 [18].  In this system, when the small molecule 
ligand binds to the nuclear receptor/GBD fusion, a conformational change recruits the 
coactivator/Gal4 activation domain fusion.  Upon the GBD binding to the Gal4 response 
elements, the GAD recruits the yeast transcriptional machinery, activating transcription 
of the selective marker and allowing for yeast survival (Figure 2.2).  Thus, chemical 
complementation links the survival of yeast to the binding of a small molecule to the 
nuclear receptor of interest [14].  There are numerous advantages of using chemical 
complementation as a system for analyzing NR/ligand pairs.  The high transformation 
efficiency for yeast on the order of 10
6
 allows for analysis of large libraries of variants.  
Yeast are simple eukaryotes, and undergo the same transcriptional processes as 
mammalian cells.  However, their lack of NRs, prevents background activation from NRs 
as observed in mammalian cells.  
Applications of chemical complementation include drug discovery, protein 
engineering, and metabolic/enzyme engineering. Drug discovery for nuclear receptors is 













Figure 2.2: Chemical Complementation Schematic.Figure 2.2: Chemical Complementation Schematic.  A yeast strain has the Gal4 
response elements control the expression of a yeast selective marker (ADE2/HIS3). 
Two fusion proteins are necessary for the system to function.  A fusion protein 
containing the NRLBD fused to a Gal4 DNA binding domain as well as a fusion 
protein containing a human coactivator fused to the Gal4 activation domain are 
needed for this system.  Upon ligand binding to the LBD the coactivator/GAD fusion 





can be used to analyze drugs for NR-based diseases in a semi high-throughput method 
[14, 15].    Using chemical complementation for drug discovery instead of mammalian 
cells eliminates the background that might be observed from NRs that are present in 
mammalian cells.  Also, a large number of drugs can be screened in a 48 hours as well as 
the fact that yeast are simple eukaryotes and therefore contain the same transcriptional 
processes as mammalian cells. 
Chemical complementation can also be used for protein engineering, specifically with 
NRs.  In the past, chemical complementation has been used to identify novel nuclear 
receptor/ligand pairs using a NR variant that has been engineered to bind a synthetic 
small molecule ligand incapable of binding the wild-type NR.  For example, the retinoid 
X receptor has been engineered to bind a novel small molecule ligand, LG335 instead of 
the wild-type ligand, 9-cis retinoic acid [15, 16].  These engineered receptors can be used 
as molecular switches in gene therapy.  In gene therapy, an exogenous gene is introduced 
into the body.  However, there needs to be a mechanism for the control of expression of 
the gene.  Therefore, the engineered nuclear receptor could be used to turn the expression 
of the gene on or off by the addition of the synthetic ligand.   
Also, the engineered nuclear receptors can be used to detect the production of small 
molecules from enzyme libraries.  This system can be used for evaluation of enzyme 
libraries in a metabolic pathway for the production of a small molecule by linking the 
survival of the yeast to the production of the small molecule.  In this system a nuclear 
receptor would be engineered to bind the target product of the enzymatic reaction.  If an 
enzyme in the library can produce the desired product, the product can bind and activate 
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the NR, causing transcription to occur and the yeast will survive.  Therefore, chemical 
complementation is a valuable method for analyzing hVDR libraries. 
2.1.3 Testing hVDR with Chemical Complementation 
The activity of hVDR in chemical complementation was determined using a fusion of 
a hVDR LBD with a GBD (pGBDhVDR) containing a tryptophan marker, and a plasmid 
containing coactivator/GAD fusion protein (pGAD10BAACTR) and a leucine marker.  
Both plasmids were transformed into the yeast strain, PJ69-4A.  Colonies were selected 
using medium lacking leucine and tryptophan, selecting for both plasmids containing the 
fusion proteins.  Yeast cells were then added to an adenine selective medium (SC-ALW) 
containing varying concentrations of ligand.  Yeast growth would indicate ligand binding 
and subsequent hVDR activation. 
hVDR was tested with 1,25(OH)2D3, lithocholic acid (LCA), and cholecalciferol.  
Cholecalciferol is an intermediate in the biosynthesis of 1,25(OH)2D3 and does not 
activate wild-type hVDR, therefore this ligand is used as a negative control [19].  The 
ligand concentration ranges tested were between 0.001 µM to 1 µM for 1,25(OH)2D3  and 
0.01 µM to 10 µM for LCA and cholecalciferol.   
EC50 values, the ligand concentration at which 50% of the maximal response is 
observed, are important for determining proper concentrations of a drug needed to be 
administered to achieve the desired effect [20].  Gal4 is as the positive control because 
this protein is a ligand activated transcription factor and should therefore grow in the 
presence or absence of ligand.  As expected, hVDR displays an EC50 value of 5 nM 
1,25(OH)2D3 in adenine selective media (SC-ALW) with an 8-fold activation based on 
growth, which is comparable to literature values in mammalian cells with an EC50 value 
31 
 
of 1 nM (Figure 2.3A) [21].  No growth was observed with LCA and cholecalciferol in 
adenine selective media (Figure 2.3B); therefore, hVDR was then tested in histidine 
selective media with LCA and cholecalciferol to determine whether a less stringent 
selection marker would allow for growth with these ligands.   
The HIS3 gene is considered a “leaky gene” in PJ69-4A, due to residual basal growth 
observed in the absence of ligand.  Basal growth is reduced by adding 3-amino 1,2,4 
triazole (3-AT) to the media, which inhibits the enzyme encoded by the HIS3 gene, 
imidazoleglycerol-phosphate dehydratase  [22].  A liquid quantitation assay was 
performed to determine the concentration of 3-AT at which basal activity would be 
reduced, allowing for ligand-activated growth.  Based on these results, 0.1 mM 3-AT was 
determined to be the optimal concentration.  At 0.1 mM 3-AT, ligand-activated growth 
was observed as well as no basal growth being observed [23]. 
      As shown in Figure 2.3C, LCA has an EC50 of > 5µM for wild-type hVDR in 
histidine selective media (SC-HLW and 0.1 mM 3AT), with 3-fold activation compared 
to the absence of ligand.  As expected, ligand-activated growth was not observed with 
cholecalciferol at any ligand concentration (Figure 2.3A and C).  Gal4 was used as the 
ligand-independent control, and colonies containing Gal4 grew in the absence and 
presence of ligand.  These results validate the application of hVDR in chemical 
complementation and are similar to literature values in mammalian cells, where LCA 
shows activation at 100 µM and cholecalciferol shows no activation [24].  Thus, chemical 

















































































































































































































































































































2.2 hVDR Library 1 
2.2.1 Background: Library Design 
A library was designed based on the crystal structure of hVDR bound to 1,25(OH)2D3 
to determine the mutational tolerance of the residues within the ligand binding pocket.  
The crystal structures were analyzed to determine residues in the LBP that were in direct 
contact with the ligand and within four angstroms [3].  Four angstroms was chosen as the 
maximal distance for contacts between the ligand and receptor in order to identify 
residues that are within the reach of a hydrogen bond (~ 1.5 Å- 3.5 Å), an electrostatic 
interaction, and a van der Waals interaction with the ligand.  Twenty amino acid residues 
were found within this distance range.  Further analysis included a consideration of 
previous mutational analysis as well as sequence alignments of the human VDR and 
other VDR orthologs to determine suitable residues for the library generation (Table 2.1).  
The partial sequence alignment, as shown in Table 2.1, shows that most hVDR LBD 
residues are conserved.  Therefore, the residues chosen to be mutated were based on the 
crystal structure of 1,25(OH)2D3 with wild-type hVDR and previous mutational analysis.  
Residues were chosen for mutation based on the structural analysis as well as residues 
that were known to form important contacts with 1,25(OH)2D3 in an effort to determine if 
what mutations would allow for wild-type activity with 1,25(OH)2D3.  Seven of the 
twenty residues were selected for mutagenesis in Library 1 in order to minimize the 
library size (Table 2.2).  The seven residues were L227, L230, L233, V234, S237, H305, 
and H397. 
2.2.2 hVDR Library 1 Design 
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The red residues are examples of conservation among different VDR orthologs.  
The orthologs are listed in the far left column.  Most residues are conserved 
between the different orthologs.  
 
Table 2.1: Sample alignment of VDR orthologs.
379 387 397
VDR_Human L Y A K M I Q K L A D L R S L N E E H S
VDR_Chicken L Y A K M I Q K L A D L R S L N E E H S
VDR_Mouse L Y A K M I Q K L A D L R S L N E E H S
VDR_Rat L Y A K M I Q K L A D L R S L N E E H S
VDR_Frog L Y A K M I Q K L A D L R S L N E E H S
VDR_Zebraf ish L Y A K M I Q K L A D L R S L N E E H S
VDR_Halibut L Y A K M I Q K L A D L R S L N E E H S
VDR_Lamprey L Y A K M I Q K L A D L R S L N E E H S
VDR_Quail L Y A K M I Q K L A D L R S L N E E H S
VDR_Tamarin L Y A K M I Q K L A D L R S L N E E H S
399 408 418
VDR_Human K Q Y R C L S F Q P E C S M K L T P L V
VDR_Chicken K Q Y R C L S F Q P E H S M Q L T P L V
VDR_Mouse K Q Y R S L S F Q P E N S M K L T P L V
VDR_Rat K Q Y R S L S F Q P E N S M K L T P L V
VDR_Frog K Q Y R S I S F L P E H S M K L T P L M
VDR_Zebraf ish K Q Y R S L S F Q P E H S M Q L T P L V
VDR_Halibut K Q Y R S L S F R P E H S M Q L T P L V
VDR_Lamprey K Q Y R S L S F Q P E H S M Q L T P L V
VDR_Quail K Q Y R C L S F Q P E H S M Q L T P L V
VDR_Tamarin K Q Y R C L S F Q P E S S M K L T P L V
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Table 2.2: Library 1 Design.  Residues and chosen mutations are listed.  The types of 
changes caused by the mutations are also listed.
Amino Acid Possible Changes Goal of Mutations










H397 HYNKQstop Polar/ charged
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      Library 1 was constructed to determine whether changing the volume of the pocket 
would modify the binding properties of the receptor.  In addition to residues with volume 
changes, the chemical properties of the residues were also modified.  For example, if 
important hydrogen bonding residues are changed to non-polar residues, an effect in 
ligand sensitivity and preference should be observed, due to the loss of hydrogen bonding 
with 1,25(OH)2D3.  L227, L230, L233, and V234 were targeted for mutation based on 
their proximity to the ligand and were modified to other hydrophobic residues, such as 
leucine, isoleucine, valine, phenylalanine, and methionine, to alter the pocket volume 
(Table 2.2).  S237, which forms a hydrogen bond with the 1α-hydroxyl group of 
1,25(OH)2D3, was modified to threonine and the more hydrophobic residues leucine, 
isoleucine, valine, phenylalanine, methionine, alanine [3].  Additionally, two histidine 
residues were also targeted: H305, which is located in a loop between helices 6 and 7, 
and H397, which is located in helix 11.  Previously, the role of H305 in the LBD of 
hVDR was determined to be significant for the binding of 1,25(OH)2D3, as  H305 is 
thought to form a hydrogen bond with the 25-hydroxyl group of the ligand.  However, 
Mizwicki et al. showed that an H305F mutant had no affect on activation by 
1,25(OH)2D3 [21, 25].  This residue was saturated to determine the significance of this 
position [3, 5].  In the case of H397, which forms a crucial hydrogen bond with the 25-
hydroxyl group of 1,25(OH)2D3, tyrosine, lysine, glutamine, and asparagine were chosen 
to determine whether a charged or polar residue would be tolerated at this position (Table 
2.1) [3, 26].  The combination of these designed mutations created a theoretical library 
size of 5.0 x 10
5
 variants.   
2.2.3 Experimental Techniques for Designing Library 
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In order to create and analyze the libraries in yeast, three components are needed:  an 
insert cassette containing hVDR variants, a background vector that contains sequences of 
homology with the insert cassette, and the coactivator/GAD fusion protein 
(pGAD10BAACTR).  Protein variants are created in vivo via homologous recombination, 
with an insert cassette and background vector with complimentary ends that allow for 
homologous recombination.  The insert cassette contains the selected mutations and the 
background vector is used for recombination and contains the Gal4 DBD.  
The background vector contains a random DNA sequence that encodes several stop 
codons to eliminate the wild-type hVDR background when transformed into yeast.  The 
background plasmid was created by initially inserting a SacII site via site-directed 
mutagenesis at the beginning of the hVDR LBD gene in pGBDhVDR and a KpnI site 
after the stop codon, creating pGBDhVDRSacIIKpnI.  pGBDhVDRSacIIKpnI was 
digested with SacII and KpnI, removing an 850 bp piece of the hVDR LBD.  DNA from 
a separate plasmid, pMSCVeGFP, was amplified with SacII and KpnI restriction sites at 
the ends, and then ligated in between the SacII and KpnI sites, creating the background 
vector (pGBDhVDRbackground) with stop codons in the reading frame (Figure 2.4).  
The background vector is linearized, allowing for recombination with the insert cassette, 
which contains complementary ends to the background vector.   
Individual oligonucleotide primers (oligos) containing degenerate base codes at the 
specific codon locations were designed and combined through hybridization and overlap 
extension PCR, to generate a library of hVDR variant insert cassettes [27].  
Oligonucleotides containing the randomized codons for the amino acid residues were 
ordered and designed, such that oligo 1 and oligo 8 contain the complementary ends to 
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the background vector.  As illustrated in Figure 2.5, the complimentary ends of oligos 1-4 
and 5-8 were created via hybridization and were amplified via PCR to create cassettes A 
and B, which were then allowed to hybridize and amplify to create the complete insert 
cassette.  The resulting insert cassette was 1014 bp. 
The plasmid containing a fusion of the human co-activator ACTR and the Gal4 
activation domain with a leucine marker (pGAD10BAACTR) as well as the background 
vector and the insert cassette was transformed into yeast.  The yeast tranformants were 
plated onto adenine selective plates (SC-ALW) with LCA and cholecalciferol [14].  
Yeast growth will be observed in the selective media if the ligand is able to bind and 
activate the hVDR variant.  Transformants were also plated onto synthetic complete 
media lacking leucine and tryptophan (SC-LW), to determine transformation efficiency 
and ensure that recombination has occurred.  The transformation efficiency was 
determined to be 1.0 x 10
6
 colony forming units/µg of vector cassette.   
2.2.4 Results of hVDR Library 1 
A library size of 1.0 x 10
5
 variants was observed when plated onto non- selective 
plates (-LW) and selective plates with LCA (SC-ALW).  Two colonies grew on the 
adenine selective plates (SC-ALW), which were then streaked onto selective plates 
without ligand in order to confirm that growth was due to ligand activation, and not a 
constitutively active hVDR variant (Figure 2.6).  In yeast, constitutive activity could 
result from the NR binding an endogenous ligand/metabolite, leading to an active 
receptor and turning on transcription of the reporter gene.  Constitutive activity could also 













































































































































































































































Figure 2.5 Using overlap extension PCR to create insert cassettes. Combining oligos 
1-4 created cassette A and oligos 5-8 created cassette B.  Cassettes A and B were then 
combined to create the full insert cassette. For= forward primer and Rev= reverse primer 
Figure 2.5 Using overlap extension PCR to create insert cassettes.  The individual 
oligos contain complimentary ends with the next oligo.  Therefore, the oligos can be 
pieced together using hybr diza ion and PCR.  Oligos 1-4 and 5-8 were hybridized and 
amplified to create cassettes A and B.  Cassettes A and B were then hybridized and 
amplified to create the full insert cassette.  Forward (For) and reverse (Rev) primers 







10-5 M Lithocholic Acid
Non-selective
Figure 2.6: Streaking of Library #1 colonies. Selective colonies were 
streaked onto adenine selective plates (-ALW) without ligand to test for 
constitutive activity. Constitutive activity is growth in the absence of 
ligand. No growth was observed on the ligand plate without ligand.  The 
colonies show ligand-activated growth with 10
-5





























































































































































































receptor in the absence of ligand.  Streaking results indicated that the two colonies were 
not constitutively active, prompting further testing in a liquid quantitation assay using 
chemical complementation as mentioned previously.   
When tested with LCA and 1,25(OH)2D3 , both variants were found to have enhanced 
sensitivity to LCA when compared to wild-type hVDR.  As shown in Figure 2.7A, these 
two variants display an EC50 value in adenine selective media (-ALW) of 0.5 µM LCA 
with 12-fold activation, while wild-type hVDR showed no growth in adenine selective 
media.  Both variants display an EC50 value of 0.5 µM LCA in histidine selective media 
with a 9-fold activation compared to wild-type hVDR, which displays an EC50 value of 
>5 µM LCA with a 3-fold activation in histidine selective media, and a 10-fold increase 
in sensitivity (Figure 2.7B).  Wild-type hVDR and the variants were analyzed for 
activation with 1,25(OH)2D3, for which EC50 values of 5 nM and 11 fold-activation were 
observed in adenine selective media for each (Figure 2.7C).   
Variants were rescued from the non-selective and selective plates and sequenced.  
The two selective variants both contained a mutation at H305, one to phenylalanine and 
the other to tyrosine.  Sequencing results indicated that of the 18 non-selective variants, 
67% contain mutations at residues H305 and H397.  94% of the variants contained 
insertions, deletions, and non-designed mutations, leading to inactive variants (Table 
2.3).  Based on the results, increased bulk of the side chains, specifically histidine to 
phenylalanine or tyrosine, leads to ligand activation, and changing the polarity at H305 
does not seem to decrease ligand activation, confirming the results observed by Mizwicki 



























































































































































































































































































































































































































































































































activation with 1,25(OH)2D3, implying that a hydrogen bond is not essential at H305 for 
activation [21, 25].  Although ligand-activated variants were not discovered with 
mutations at the other residues chosen in the library, a conclusion of tolerance at these 
positions could not be made due to the fact that a complete library of variants was not 
achieved. 
LCA was docked into wild-type hVDR and H305F using AutoDock Vina in order to 
visualize the influence of these mutations on ligand binding through in silico methods 
(Figure 2.8) [28].  The structures of the hVDR variants were prepared in silico using the 
program TRITON 4.0.0 (National Centre for Biomolecular Research, Czech Republic) 
and its external program MODELLER (National Centre for Biomolecular Research, 
Czech Republic).  The computational site-directed mutagenesis method, which is based 
on using the wild-type protein for homology modeling was implemented [29, 30].  
Homology modeling analyzes all of the crystal structures in the PDB, creating an 
algorithm of the residue conformations based upon residues in proximity to the residue of 
interest.  For example, based on all of the crystal structures, leucine has been found to 
prefer a certain conformation when this residue is next to an alanine or a tryptophan. 
To develop models for analysis, the wild-type hVDR crystal structure (PDB:1DB1) 
was used as the template [3].  Variants were prepared for docking using the UCSF 
CHIMERA- interactive molecular graphics program by: (1) removing the ligand and 
water molecules, (2) adding polar hydrogens, and (3) assigning Gasteiger charges, which 
sets the partial charge property of each atom [31]. Ligands were created using 
ChemBioDraw Ultra 11.0 and ChemBio3D Ultra 11.0 (Cambridge Soft, USA) and 











Figure 2.8: wthVDR and H305F docked with Lithocholic Acid.
wt= green (residues) and cyan (ligand).  H305F= salmon (residues)
and purple (ligand).
Figure 2.8: wthVDR and H305F docked with Lithocholic Acid. wt= green 
(residues) and cyan (ligand).  H305F= salmon (residues) and purple (ligand). 
Figure 2.8: wthVDR and H305F docked with Lithocholic Acid. Wild-type 
hVDR= green (residues) and cyan (ligand).  H305F= salmon (residues) and 
purple (ligand).  A shift in the carboxyl group of LCA can be seen in the H305F 
docking.  Also, a shift of the liagnd towards Y143 can be seen in the H305F 
docking when compared to LCA docked to wild-type hVDR. 
 
Fig e 2.8: wthVDR and H305F docked with lithocholic acid. Wild-type 
hVDR= green (residues) and cyan (ligand).  H305F= salmon (residues) and purple 
(ligand).  A shift in the carboxyl group of LCA can be seen in th  H305F docking.  
Also, a shift of the ligand towards Y143 can be seen in the H305F docking when 
compared to LCA docked to wild-type hVDR. 
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property of each atom [32]. AutoDock Vina was used to perform docking simulations 
with default parameters, such as search area and time spent searching the area for 
conformations [28]. The solutions exhibiting the lowest free energy of binding were 
analyzed. 
       In silico modeling of 1,25(OH)2D3 was used as the control to verify that the 
modeling method works.  In silico modeling results indicated that the H305F and H305Y 
variants cause a shift in the position of LCA in the ligand binding pocket.  When 
comparing the superimposition of the docked structures of wild-type hVDR and H305F 
bound to lithocholic acid (Figure 2.8), a shift in the LCA ring system towards Y143 and a 
repositioning of the carboxyl group of LCA is observed.  The bulkier residues, 
phenylalanine (189.9 Å
3
) or tyrosine (196.3 Å
3
), in the place of histidine (153.2 Å
3
), lead 
to an increase in volume at position 305 [33].  This increase seems to contribute to the 
repositioning and shifting of the ligand, resulting in closer interactions between residues 
in the pocket and LCA, thus enhancing sensitivity with this ligand [25, 33].  H305F and 
H305Y were subjected to further mutagenesis to engineer a hVDR variant capable of 
binding and activation in response to cholecalciferol. 
Based upon previous work by Mizwicki et al. the replacement of H305 with a non-
polar aromatic residue, phenylalanine, was expected to affect sensitivity to LCA, as their 
observations indicate that the H305F mutation does not affect activation with 
1,25(OH)2D3 [21, 25].  H305F has also been shown to reverse ligand activity by turning 
the hVDR antagonist, (23S)-25-dehydro-1-(OH)-vitamin D3-26,23-lactone (MK), into a 
superagonist, which means activation with MK occurs at a lower concentration relative to 
wild-type hVDR activation with 1,25(OH)2D3.  This is believed to occur because MK 
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requires less space in the LBP than 1,25(OH)2D3  and therefore does not create the 
necessary contacts with H305 that are needed to obtain activation [25].  However, 
increasing the bulk at this position with a phenylalanine allows for additional contacts 
with the 305 residue, due to the decrease of LBP volume, resulting in ligand activation.  
The same concept is believed to apply with LCA, as the smaller ligand LCA is predicted 
to have fewer contacts with H305 but increased contacts with H305F.  The H305F variant 
of hVDR displays an increased sensitivity toward LCA in comparison to wild-type.  As 
LCA is smaller than 1,25(OH)2D3, the appearance is that bulkier residues, such as 
phenylalanine or tyrosine may be optimizing the interactions with LCA in comparison to 
H305.  These mutations do not affect activation with 1,25(OH)2D3, suggesting that the 
ligand/receptor contacts are maintained for binding and activation. 
2.3 hVDR Library 2 
As mentioned previously, twenty residues were found within four angstroms of 
1,25(OH)2D3 in the hVDR ligand binding pocket.  However, Library # 1 contained only 
seven residues in order to minimize library size.  Accordingly, five more residues from 
the twenty were chosen as targets in library 2: Y143, R274, S275, S278, and W286 
(Figure 2.1, Table 2.4).  The goal of this library was to challenge the volume, shape, and 
polarity of the pocket with residues that could not be included in Library 1.  All of the 
residues with the exception of W286 are believed to be involved in hydrogen bonding 
with the ligand based upon previous alanine scanning mutagenesis.  The mutations 
chosen for each residue can be found in Table 2.5.  Y143, which forms a hydrogen bond 
to the 3-hydroxyl group of 1,25(OH)2D3, was subjected to saturation mutagenesis to test 




Table 2.4: Library 2 Design. Residues and chosen mutations are listed.  The types 
of changes caused by the mutations are also listed.
Amino Acid Mutations Goal of Mutations
Y143 saturated all
R274 LIV2FMA2S2 T2CRWG2 Hydrophobic/volume/polar
S275 LIV2FMA2S2 T2 Hydrophobic/volume/polar




which also form hydrogen bonds to 1,25(OH)2D3, were mutated to hydrophobic residues 
in order to modify the polarity of the pocket.  W286 was mutated to two non-aromatic 
residues (leucine and cysteine) and two aromatic residues (phenylalanine and 
tryptophan).  The theoretical library size (based on amino acids) was 6.1 x 10
4
 variants.  
The same approach was used to create these cassettes as was used with Library 1, and 
these variants were transformed into yeast.  A library size of 1.1 x 10
3
 variants was 
observed.  However, no variants displayed growth on histidine selective plates.  To 
determine the library’s diversity, six non-selective colonies were sequenced.  Sequencing 
analysis revealed that diversity was observed, and approximately 66% of the variants 
displayed insertions, deletions, and undesigned mutations (Table 2.5), indicating a flaw in 
the overlap extension and hybridization protocol for creating the insert cassettes. 
2.4 hVDR Library 3 
Library 3 focused primarily on the role of hydrogen bonding in ligand activation of 
hVDR (Figure 2.1).  All hydrogen bonding residues from Libraries 1 and 2 were 
combined into one library to assess the effect when these residues were mutated to non-
hydrogen bonding residues.  The designed mutations remained the same as in the 
previous libraries: Y143 and H305 were subjected to saturation mutagenesis, and S237, 
R274, and S278 were mutated to hydrophobic residues.  H397 was mutated to tyrosine, 
lysine, glutamine, and asparagine (Tables 2.2, 2.4).  The theoretical library size was 2.0 x 
10
6
 variants and a library size of 2.3 x 10
3
 variants was observed, after transforming the 
variants into yeast.   
Two variants were observed on histidine selective plates with LCA.  These variants 





Table 2.5: Library #2 Sequencing. Residues that were not changed are shown as wt. Mutations 
are shown along with the codon change. As can be observed, diversity is observed at the 
positions that were chosen for mutation.
Saturated LIVFMASTCRWG LIVFMAST LIVFMAST FWLC
Variant
Y143 R274 S275 S278 W286
1 stop M(ATG) wt L(TTG) C(TGT)
2 S(TCG) A(GCC) V(GTC) F(TTT) L(TTG)
3 E(GAG) V(GTC) A(GCT) T(ACC) L(TTG)
4* T(ACG) T(ACC) L(CTG) A(GCG) wt
5 P(CCG) W(TGG) I(ATC) V(GTG) C(TGC)
6 A(GCT) M(ATG) V(GTG) I(ATC) wt






Figure 2.9: Library # 3 Streaking. Streaking selective colonies onto
histidine selective media (-HLW w/ 0.1 mM 3-AT) to test for constitutive activity.  
Both colonies are constitutively active.
Figure 2.9: Library # 3 Streaking. Streaking selective colonies onto 
histidine selective media (-HLW w/ 0.1 mM 3-AT) to test for constitutive 
activity.  Both colonies are constitutively active. 
 
Figure 2.9: Library # 3 Streaking. Str aking selective 
coloni s onto histidine selective media wi hout ligand (-
HLW w/ 0.1 mM 3-AT) to test for constitutive activity.  




ligand.  As seen in Figure 2.9, both colonies were constitutively active showing growth in 
the absence of ligand.  Based upon sequencing of variants from the library, 84% of the 
sequenced colonies contained insertions, deletions, or undesigned mutations (Table 2.6).  
Both constitutively active variants were terminated prior to the stop codon at Q239, 
leading to a truncated protein. This was surprising, considering that helix 12 is known to 
be crucial for NR receptor activation.  
2.5 Summary 
hVDR was engineered for a better understanding of the mutational tolerance of the 
pocket, as well as further characterizing the residues necessary for ligand activation.  
Three libraries were created in an attempt to better understand the interactions between 
hVDR and LCA.  In Library 1, two variants, H305F and H305Y, were discovered with an 
increased sensitivity towards LCA, and Libraries 2 and 3 did not produce any variants 
capable of ligand activation.  However, diversity in the libraries was observed, along with 
insertions, deletions, and undesigned mutations.  Therefore, chemical complementation 
was shown to be a useful tool to analyze hVDR libraries.  The two variants, H305F and 
H305Y, give some insight into the tolerance of position H305 in terms of ligand binding 
and activation.  In an attempt to engineer hVDR variants capable of binding a novel small 
molecule, the two variants from Library 1 were subjected to multiple cycles of 
mutagenesis for protein engineering.  






















































































































































































































































































































































































Lithocholic acid, cholecalciferol, and 1α,25-dihydroxyvitamin D3 were ordered from MP 
Biomedicals, LLC (Solon, OH), Sigma-Aldrich (St. Louis, MO), and BIOMOL 
(Plymouth Meeting, PA), respectively.  10 mM stocks of lithocholic acid and 
cholecalciferol and a 13.3 µM stock of 1α,25-dihydroxyvitamin D3 were made with 80% 
ethanol: 20% DMSO as the solvent and stored at 4 °C.   
2.6.2 Creating Designed hVDR Library 
To create the hVDR insert cassette variants, oligonucleotides with overlapping ends, 
containing degenerate base codes at the chosen positions, were pieced together using 
overlap extension PCR (Figure 2.4, Tables 2.7, 2.8, 2.9) [27].  100 ng of each oligo and 
125 ng of each primer were combined in a PCR tube and subjected to a PCR program 
with the following conditions: 95 °C for 1 min, 59 °C for 1 min, 72 °C for 2 min, 15 
cycles, 95 °C for 1 min, 56.6 °C for 1 min, 72 °C for 2 min, 15 cycles.  The resulting 
insert cassette was 1014 bp. 
To create a background vector cassette, site-directed mutagenesis was used to insert 
SacII and KpnI sites into pGBDhVDR 810 bp apart, resulting in the 
pGBDhVDRSacIIKpnI plasmid.  This plasmid was digested with the two restriction 
enzymes, removing 810 bp of the wild-type VDR gene from the plasmid.  A 145 bp 
segment of random DNA from another plasmid, pMSCVeGFP, was digested and ligated 
between the SacII and KpnI sites (pGBDhVDRSacIIKpnI), generating 3 stop codons in 
the open reading frame.  The resulting plasmid was named pGBDhVDRbackground and 
confirmed by sequencing (Operon, USA).   








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Using the 1x TRAFCO yeast transformation protocol [34], 0.1 µg of the digested 
background plasmid (pGBDhVDRbackground) and 0.9 µg of insert cassette were 
transformed into the yeast strain PJ69-4A.  A plasmid containing a fusion of the human 
co-activator ACTR and the Gal4 activation domain with a leucine marker was also co-
transformed [14].  Transformants were plated onto synthetic complete (SC) agar plates 
lacking adenine, leucine, and tryptophan (SC-ALW) with various ligands.  Synthetic 
complete plates are made using yeast nitrogenous base, ammonium sulfate, dextrose 
anhydrous, and dropout powder.  The dropout powder used does not contain uracil, 
tryptophan, adenine, leucine, or histidine.  Transformants were also plated without ligand 
onto synthetic complete agar plates lacking leucine and tryptophan (SC-LW) to 
determine transformation efficiency.  Transformation efficiency was calculated based 
upon the number of colonies on the plate divided by the µg of vector cassette that was 
plated onto each plate.   
2.6.4 Liquid Quantitation Assay of hVDR in Yeast 
Variants were tested in liquid quantitation assays in 96-well plates with media lacking 
adenine, leucine, and tryptophan (SC-ALW), with or without LCA, cholecalciferol, or 
1,25(OH)2D3 at varying concentrations (ranging from 0.01 µM - 10 µM for LCA and 
cholecalciferol, 1 nM - 1 µM for 1,25(OH)2D3).  A 4:1 ratio of media (SC-ALW): cells 
(yeast resuspended in water) were aliquoted into 96-well plates.  Plates were incubated at 
30°C, with shaking at 170 rpm.  Optical density (OD) readings at 630 nm were recorded 
at 0, 24, and 48 hours to measure turbidity. 
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ENGINEERING HUMAN VITAMIN D RECEPTOR TO BIND AND 
ACTIVATE IN RESPONSE TO CHOLECALCIFEROL 
 
 
3.1 Random Mutagenesis 
Cholecalciferol, an intermediate in the 1,25(OH)2D3 biosynthetic pathway, was 
chosen as the target novel small molecule for protein engineering due to the similarities 
with 1,25(OH)2D3, as well as the inactivity with wild-type hVDR.  Cholecalciferol lacks 
the 1α and the 25-hydroxyl groups that are present in 1,25(OH)2D3, which reduces 
hydrogen bonding potential between cholecalciferol and the surrounding residues.  Due 
to cholecalciferol’s similar structure to 1,25(OH)2D3 and this ligands inability to activate 
wild-type hVDR, cholecalciferol was chosen as the target small molecule for hVDR 
engineering in an attempt to better understand the structure/function relationship between 
hVDR and the role of various residues in the ligand binding pocket.  A determination of 
which residues are necessary to compensate for the lack of hydrogen bonding potential 
present in cholecalciferol could lead to a better understanding of the interactions that are 
necessary between hVDR and various ligands to obtain activation.  In an attempt to 
obtain a hVDR variant that could bind cholecalciferol, random mutagenesis was 
performed using wild-type hVDR, H305F, and H305Y as starting templates based on 
their unique activation profiles, including the increased sensitivity of H305F and H305Y 
towards lithocholic acid.   
Directed evolution is used in protein engineering to create mutants with desired 
functions that are nonexistent in nature.  Directed evolution has emerged as a widely used 
method for protein engineering [1-4].  As a result, libraries of proteins can be created by 
rational or random mutagenesis [5, 6].  In rational design, structural analysis, mechanistic 
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and functional analyses of the targeted protein are required to make an informed decision 
regarding which residues to mutate in an attempt to engineer the protein for a certain 
function [7, 8].  However, random mutagenesis allows for a predominately unbiased 
library as well as a larger mutational spectrum (i.e. mutations not limited to the active 
site).  Although rational design is a widely used method for protein engineering, a large 
amount of information is needed to accurately design a protein library, while random 
mutagenesis does not require the information that rational design needs.  However, 
rational design does allow for more control over the variants that are produced than 
random mutagenesis 
One method for random mutagenesis is DNA shuffling.  In DNA shuffling, related 
sequences are digested by DNaseI to form a pool of DNA fragments [9, 10].  Mutations 
occur when a fragment from one gene anneals with a fragment from another gene.  These 
recombinations create a library of chimeric genes, some of which may give the desired 
protein function [9, 10].  The staggered extension process (StEP), which increases the 
gene length over repeated cycles of PCR by annealing templates with complimentary 
ends is a method of random mutagenesis [11].  The extension process allows the primers 
to anneal to different templates and creating a library of chimeras [11].  Random drift 
mutagenesis involves the incorporation of neutral mutations into the proteins of interest 
[12]. 
Random mutagenesis, specifically error-prone PCR, was chosen over rational design 
to determine whether mutations beyond the four angstrom bias employed in the rational 
library design could lead to an ideal conformation, inducing activation of hVDR with 
cholecalciferol [13].  In this method, the gene of interest is subjected to a PCR reaction, 
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with a polymerase possessing a low fidelity (typically Taq polymerase) and lacking 
proofreading capability [14].  The addition of MnCl2 further diminishes the polymerase’s 
fidelity, as the manganese displaces the Taq polymerase’s coordinating magnesium metal 
involved in stabilizing the enzyme [14-17].  Previously, error-prone PCR has been shown 
to be successful in the protein engineering of nuclear receptors for new receptor/ligand 
pairs, as was observed with the estrogen receptor and the synthetic ligand, 4,4'-
dihydroxybenzil (DHB) [18-20].  
3.2 Error-Prone Library 
3.2.1  Experimental Techniques in Creating Library of Variants 
A plasmid containing a Gal4DBD (GBD) fused to the hVDR variant, H305F 
(pGBDH305F), was used as the template DNA for error-prone PCR random mutagenesis.  
H305F was used as the template due to H305F’s increased sensitivity towards LCA.  
Primers starting at the beginning of the gene and extending to the 3’UTR of the H305F 
gene were used to amplify the insert cassette.  MnCl2 was used to create a library of 
variants and the insert cassette and background vector were then co-transformed into the 
yeast strain PJ69-4A [21].  Via homologous recombination, the insert cassette and 
linearized background vector should yield a library of variants in the yeast.  The 
transformants were plated onto adenine selective plates (SC-ALW) with LCA and 
cholecalciferol respectively, as well as non-selective plates (SC-LW) to determine 
transformation efficiency.   
3.2.2 Results of Error-Prone Library 
The variants were selected using chemical complementation, a system in which 
cholecalciferol binding a hVDR variant induces the recruitment of the coactivator/Gal4 
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activation domain fusion (GAD).  The coactivator/GAD fusion will recruit the 
transcriptional machinery allowing the yeast to survive on media lacking adenine (SC-
ALW).   
This library displayed a transformation efficiency of 4.0 x 10
2
 colony forming 
units/µg of vector cassette and a library size of 4.2 x 10
3 
variants.  Only one variant 
showed growth on adenine selective plates containing 10 µM cholecalciferol.  This 
variant was tested for constitutive activity.  As shown in Figure 3.1, growth was observed 
on the non-selective plate, as expected, since the non-selective plate selects for the two 
fusion plasmids.  However, no growth was observed on the adenine selective plate 
without ligand, indicating that the variant is not constitutively active (Figure 3.1).  The 
variant was rescued and sequenced, and sequencing showed that an additional mutation, 
H397Y, was added to the H305F template, creating the double variant H305F/H397Y. 
To further characterize the variant, a liquid quantitation assay was performed.  Yeast 
cells were added to adenine selective media with varying concentrations of LCA, 
cholecalciferol, and 1,25(OH)2D3 .  H305F/H397Y showed activation at an EC50 value of 
0.5 µM and 10-fold activation with LCA, as well as an EC50 value of >5 µM and 7-fold 
activation with cholecalciferol in adenine selective media (Figure 3.2).  As shown in 
Figure 3.2A, Gal4, which is a ligand-independent transcription factor, grows as expected 
at all concentrations.  H305F, H305Y, and H305F/H397Y display ligand-activated 
growth with LCA at an EC50 value of 0.5 µM and with an about 11-fold activation, 




Figure 3.1:  Streaking of Error Prone Selective colony. (A) Yeast growth 
should be observed on the non-selective plate (-LW).  (B) Yeast growth is 
not observed on the adenine selective plate in the absence of ligand, 
implying that the variant is not constitutively active.
-LW -ALW
Figure 3.1:  Streaking of Error Prone Selective colony. One selective colony 
grew on the lective plates.  This colony was th n streaked to test for 
constitutive activity.  (A) Yeast growth should be observed on the non-selective 
plate (-LW).  (B) Yeast growth is not observed on the adenine selective plate in 




































































































































































































 H305F/H397Y is the only variant that displays ligand-activated growth with 
cholecalciferol with an EC50 value of 5 µM and a 7 fold-activation in adenine selective 
media (Figure 3.2B) 
These results were surprising as previous mutational analysis had shown that H397 
forms an essential hydrogen bond with the 25-hydroxyl group of 1,25(OH)2D3, a bond 
not present in cholecalciferol.  However, the combination of both mutations in the double 
variant results in an increase in bulk, since phenylalanine (189.9 Å) and tyrosine (196.3 
Å) are bulkier than histidine (153.2 Å), hence decreasing the overall volume of the ligand 
binding pocket [22].  This suggests that a combination of volume changes as well as the 
presence of hydrogen bonding residues in the pocket at residues 305 and 397 leads to 
binding and activation with cholecalciferol, as seen with the H305F/H397Y mutant.  
With 1,25(OH)2D3, H305F/H397Y displayed and EC50 value of 5 nM in adenine selective 
media with a 9-fold activation, which is the same as wild-type hVDR, H305F, and 
H305Y (Figure 3.2C). 
3.2.3 Testing Variants in Mammalian Cell Culture 
To determine whether the variants discovered with chemical complementation 
display the same or similar activity in mammalian cell assays, the variants were analyzed 
in human embryonic kidney 293T cells (HEK293T).  HEK293T cells (ATCC, USA) 
were transfected with the following plasmids:  pCMXwthVDR, pCMXH305F, 
pCMXH305Y, and pCMXH305F/H397Y.  These plasmids contain the Gal4DBD (GBD) 
fused to the corresponding VDR ligand binding domain (GBD:LBD fusion under the 
control of a cytomegalovirus (CMV) promoter).  The reporter plasmids used were 
p17*4TATAluc, containing the Renilla luciferase gene, and pCMXβgal, containing the β-
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galactosidase gene, which allows for the determination of efficiency of the transfection.  
Lipofectamine 2000 served as the cationic lipid, which aids in the transmembrane 
transport of the plasmids.  Ligands are added at various concentrations (0.01 µM- 100 
µM LCA and 0.01 µM- 32 µM cholecalciferol), and cells are harvested and analyzed for 
luciferase and β-galactosidase activity, which allows for the calculation of transfection 
efficiency.   
As shown in Figure 3.3, hVDR variants H305F and H305Y display activation at 3.3
 
µM LCA and 1
 
µM, respectively, in comparison to 100
 
µM LCA for wild-type hVDR as 
seen in yeast.  H305F and H305Y show 40- and 74- fold activation, respectively, with 
LCA, whereas wild-type hVDR shows a 13-fold activation with LCA only at the highest 
concentration (100 µM) of ligand (Figure 3.3, Table 3.1).  The H305F/H397Y variant has 
a 100-fold increase in sensitivity with LCA showing activation at 1 µM in comparison to 
100 µM with wild-type hVDR and LCA.  Additionally, H305F and H305Y display 
activation at 1 µM cholecalciferol resulting in a 54- and 65- fold activation, whereas no 
activation is observed with cholecalciferol and wild-type hVDR.   
As can be seen in Table 3.1, EC50 values of 10 μM for LCA and 3 μM for 
cholecalciferol were observed with both H305F and H305Y, whereas, EC50 values for 
wild-type hVDR with both LCA and cholecalciferol were 100 µM or greater.  The second 
generation double variant, H305F/H397Y, shows an EC50 value similar to that of H305F 
with LCA (10 µM), but an EC50 value of 300 nM is observed with cholecalciferol, in 
comparison to the 3 µM EC50 value for H305F.  Thus, we have engineered a variant of 
hVDR that is now activated by submicromolar concentrations of cholecalciferol, along 






Figure 3.3: Testing variants in mammalian cell culture. Wild-
type hVDR, H305F, H305Y, and H305F/H397Y were tested in cell 
culture.  (A) Lithocholic Acid and (B) Cholecalciferol
Figur  3.3: Testing variants in ma malia l  culture. Wild-
type hVDR, H305F, H305Y, and H305F/H397Y were tested in cell 
culture.  (A) Variants display activation with LCA beginning at 10 
µM in comparison to 100 µM for wild-type.  (B) H305F/H397Y 
displays a 10-fold increase in sensitivity towards cholecalciferol in 




Table 3.1: EC50 values and fold-activations of wthVDR and variants
in mammalian cells (HEK293T).
Lithocholic Acid Cholecalciferol
HEK293T HEK293T
Variant EC50 FA EC50 FA
Wild-Type 100 μM 13 + 7 >100 μM 3 + 1
H305F 10 μM 40 + 14 3 μM 54 + 11
H305Y 10 μM 74 + 25 3 μM 65 + 6
H305F/H397Y 10 μM 84  + 14 0.3 μM 70 + 11
74 
 
 3.2.4 Modeling of Variants with Cholecalciferol 
 To visualize the impact of these mutations on ligand binding through in silico 
methods, cholecalciferol was docked into wild-type hVDR, H305F, and H305F/H397Y 
using AutoDock Vina, as described in the materials and methods (Figure 3.4) [23].  In the 
superimposition of wild-type hVDR and the variants with cholecalciferol, a drastic 
change is observed among these structures.  Cholecalciferol, in the docked structures, 
shows a 180° rotation in the binding pocket when compared to the crystal structure of 
wild-type hVDR and 1,25(OH)2D3.  The 3-hydroxyl group of 1,25(OH)2D3 has been 
shown to interact with S237 and R274, the 1α-hydroxyl group has been shown to interact 
with Y143 and S278, and the 25-hydroxyl group has been shown to interact with H305 
and H397.  Y143 has been implicated in ligand stabilization in the pocket, and the 
absence of the 1α-hydroxyl group allows the ligand to rotate.   Previously Yamada et al. 
observed a 180° shift with 3-ketolithocholic acid in the hVDR pocket, similar to the 
observations with cholecalciferol (Figure 3.4A) [24].  
In silico structures with cholecalciferol bound to wild-type hVDR (Figure 3.4A) also 
display a bent conformation of the ligand in comparison to the crystal structure of hVDR 
with 1,25(OH)2D3, suggesting that a bowl-shaped conformation is preferred in order for 
the ligand to create the necessary contacts for binding and activation [25-27].  Therefore, 
the bent conformation with cholecalciferol and wild-type hVDR may be leading to an 
inferior conformation resulting from the absence of crucial contacts with R274, Y143, 
and S278 (Figure 3.4A).   The absence of crucial contacts is most likely the cause for the 










































































































































































































































































































































In the case of the double variant H305F/H397Y, the combination of both mutations 
causes cholecalciferol to shift away from the tyrosine at residue 397.  The presence of a 
tyrosine at position 397 instead of a histidine leads to a decreased binding pocket volume 
(Figure 3.4B).  In the double variant, when comparing the spacefill model of histidine 
and tyrosine at 397, the bulkier tyrosine results in an upward shift of the cholecalciferol 
in the pocket, perhaps allowing for more favorable van der Waals interactions between 
cholecalciferol and the residues in the pocket.  In the docked structures, the hydroxyl 
group of cholecalciferol is unlikely to be within hydrogen bonding distance of the 
histidine (6.09 Å) or tyrosine (6.59 Å) of the variants.  However, this could be an artifact 
of the docking program as the protein remains static during docking; therefore, the 
residues may be in a different conformation and may be able to form a hydrogen bond 
with cholecalciferol.  In addition, water molecules are known to form hydrogen bonds 
with ligands, such as in the case of rat VDR [24, 28].  Thus, a water molecule may be 
present in the ligand binding pocket capable, of forming a hydrogen bond with H397Y 
and cholecalciferol [24].  Thus, the increase in bulk at 397 also increases the favorable 
hydrophobic van der Waals interactions between residue 397 and F422, an important 
residue in the AF-2 domain of hVDR.  This may be leading to a stabilizing effect, such as 
tighter co-activator binding, as shown previously [29, 30].  The H397-F422 bridge 
creates a 19 Å distance between E420 on the AF-2 and K246 of helix 3.  This charge 




When H305F was subjected to random mutagenesis using error-prone PCR in order 
to discover a variant capable of binding cholecalciferol, a double variant, H305F/H397Y, 
displayed LCA activation profiles similar to those of H305F but a ~10-fold increased 
sensitivity towards cholecalciferol, displaying an EC50 of 300 nM in mammalian cells 
(Figure 3.2, 3.3).  In silico docking of cholecalciferol to the H305F variant using 
AutoDock Vina displays a less linear conformation for cholecalciferol in comparison to 
the same ligand bound to wild-type hVDR (Figure 3.4A) [23].   
In conclusion, more insight into the relationship and crucial interactions between 
hVDR and various ligands has been acquired.  These results have shown that hydrogen 
bonding at H397 is necessary for binding and activation with cholecalciferol.  Also, the 
180° flip of cholecalciferol in the ligand binding pocket suggests that the hydrogen 
bonding potential at the H305/H397 end of the pocket is also important for stabilizing 
cholecalciferol and allowing for ligand activation.  Single point mutations at position 305, 
H305F and H305Y, result in an increased sensitivity with LCA and cholecalciferol.  A 
hVDR variant, H305F/H397Y, is able to bind cholecalciferol at submicromolar 
concentrations in mammalian cells, whereas wild-type hVDR does not display activation 
with this ligand.  Additionally, the H397Y mutation in combination with H305F, 
introduces a modification in the volume of the pocket, leading to activation with 
cholecalciferol.  Future work, including in vitro binding studies, as well as additional 
mutational analysis, to determine if the tyrosine is necessary for maximal activation with 
cholecalciferol will be performed.  This will allow a more comprehensive understanding 




3.4 Materials and Methods 
3.4.1 Ligands 
Lithocholic acid, cholecalciferol, and 1α,25-dihydroxyvitamin D3 were ordered from 
MP Biomedicals, LLC (Solon, OH), Sigma (St. Louis, MO), and BIOMOL (Plymouth 
Meeting, PA), respectively.  10 mM stocks of lithocholic acid and cholecalciferol and a 
13.3 µM stock of 1α,25-dihydroxyvitamin D3 were made with 80% ethanol: 20% DMSO 
and stored at 4 °C. 
3.4.2 Error-Prone PCR 
pGBDhVDRH305F, the plasmid containing the hVDR mutant, was used as the 
template DNA, for error-prone PCR random mutagenesis with primers:  
5’-gatcctgaagcggaaggagg-3’ and  
5’-gtccaggcagggtggccagaacgggtgggcacaaaggatggactagttcaggagatctcattgccaaacacttcgag-
3’.  0.5 μM of each primer, 500 μM dNTPs, 7 mM MgCl2, 20 μM MnCl2, 250 ng 
template DNA (pGBDhVDRH305F), 1x Taq buffer, and 5 units of Taq polymerase 
(Fermentas, USA) were used for each reaction.  The PCR program used was: 95 ºC for 5 
min, 95 ºC for 30 sec, 55 ºC for 30 sec, 72 ºC for 60 sec, 20 cycles yielding ~ 1 µg of 
variant VDR insert cassette.  The insert cassettes were then transformed into yeast using 
the 1x TRAFCO protocol and tested in liquid quantitation assays using chemical 
complementation as mentioned in Schwimmer et al. [31].   
3.4.3 Yeast Transformation 
     Using the 1x TRAFCO yeast transformation protocol [32], 100 ng of  the digested 
background plasmid (pGBDhVDRbackground) and 900 ng of insert cassette were 
transformed into the yeast strain PJ69-4A.  A plasmid containing a fusion of the human 
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co-activator ACTR and the Gal4 activation domain with a leucine marker was also co-
transformed [21].  Transformants were plated onto synthetic complete (SC) agar plates 
lacking adenine, leucine, and tryptophan (SC-ALW) with various ligands.  Transformants 
were also plated onto synthetic complete agar plates lacking leucine and tryptophan (SC-
LW) containing no ligand, to determine transformation efficiency.  Transformation 
efficiency was calculated based on the number of colonies on the plate divided by the µg 
of vector cassette that was plated onto each plate.   
3.4.4 Liquid Quantitation Assay in Yeast 
     Variants were tested in liquid quantitation assays in 96-well plates with media lacking 
adenine, leucine, and tryptophan (SC-ALW), with or without LCA, cholecalciferol, or 
1,25(OH)2D3 at varying concentrations (ranging from 10 nM - 10 µM for LCA and 
cholecalciferol, 1 nM - 1 µM for 1,25(OH)2D3).  A 4:1 ratio of media (SC-ALW): cells 
(yeast resuspended in water) were aliquoted into 96-well plates.  Plates were incubated at 
30°C, with shaking at 170 rpm.  Optical density (OD) readings at 630 nm were recorded 
at 0, 24, and 48 hours as a measure of growth density. 
3.4.5 Mammalian Cell Culture 
     HEK293T cells (ATCC, USA) were transfected with the following plasmids:  
pCMXwild-type hVDR, pCMXH305F, pCMXH305Y, and pCMXH305F/H397Y.  These 
plasmids contain the Gal4DBD (GBD) fused to the corresponding VDR ligand binding 
domain (GBD:LBD fusion under the control of a cytomegalovirus (CMV) promoter).  
The reporter plasmids were p17*4TATAluc, containing the Renilla luciferase gene under 
the control of four Gal4 response elements located upstream from a minimal thymidine 
kinase promoter, and pCMXβgal, a plasmid containing the β-galactosidase gene under 
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the control of the mammalian CMV promoter.  Lipofectamine 2000 (Invitrogen, USA) 
served as the cationic lipid and transfection experimental details are described in Taylor 
et al. [33].  The ligands were added to the wells at various concentrations ((0.01 µM- 100 
µM) LCA and (0.01 µM- 32 µM) cholecalciferol).  Cells were harvested and analyzed for 
luciferase and β-galactosidase activity.  All data points represent the average of triplicate 
experiments normalized against β-galactosidase activity.  Error bars represent the 
standard deviation calculated using standard deviation: σ = Square root (Σ[(X-µ)
2
]/N).  
Fold activation was calculated by dividing the value at maximal activation by the value at 
the no ligand data point.   
3.4.6 Docking hVDR Variants 
     The structures of the hVDR mutants were prepared in silico using the program 
TRITON 4.0.0 (National Centre for Biomolecular Research, Czech Republic) and its 
external program MODELLER (National Centre for Biomolecular Research, Czech 
Republic).  These programs do not include any molecular dynamics.  The computational 
site directed mutagenesis method, which is based on using the wild-type protein for 
homology modeling was employed [34, 35].  The wild-type hVDRLBD from the crystal 
structure 1DB1 was used as the template, which is missing residues 165-215 for 
crystallization purposes [36].  These residues were not added computationally in the 
modeling process. 
     Variants were prepared for docking using the UCSF CHIMERA- interactive 
molecular graphics program by: (1) removing the ligand and water molecules, (2) adding 
polar hydrogens, and (3) assigning Gasteiger charges [37]. Ligands were created using 
ChemBioDraw Ultra 11.0 and ChemBio3D Ultra 11.0 (Cambridge Soft, USA) and 
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modified with the AutoDockTools by adding Gasteiger charges, setting the partial charge 
property of each atom [38]. AutoDock Vina was used to perform docking simulations 
with default parameters [23]. In the Autodock simulations the hVDR ligand binding 
domain was held rigid while the ligand was allowed to rotate, based on quantum 
mechanical rotations that are incorporated into the algorithm.  For the ligands the C3-OH 
bond, the carbon chain connecting the two ring systems, and the aliphatic chain extending 
off of C17 were allowed to rotate freely in the simulations.  The solutions with the lowest 
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As shown in Chapters 2 and 3, three variants, H305F, H305Y, and H305F/H397Y 
were discovered to have a 100-fold increased sensitivity towards lithocholic acid in 
comparison to wild-type, where an EC50 of 10 µM and fold activations of 40 + 14 and 74 
+ 25 were observed for H305F and H305Y, respectively in mammalian cells.  
H305F/H397Y, displays a 10-fold increase in sensitivity with cholecalciferol, with an 
EC50 of 0.3 µM and a 70 + 11 fold activation was observed, whereas wild-type hVDR 
shows no activation with cholecalciferol in mammalian cells.  Due to these results, 
lithocholic acid and cholecalciferol were modeled using Auto Dock Vina into the ligand 
binding pocket of wild-type hVDR in an attempt to visualize the most obvious 
differences between these ligands in the pocket in comparison to 1,25(OH)2D3 [1].  As 
can be seen in Figure 4.1A, lithocholic acid does not occupy as much space in the LBP 
when compared to 1,25(OH)2D3.  Therefore, decreasing the volume of the LBP should 
allow for increased sensitivity of the receptor towards LCA in comparison to wild-type 
hVDR by creating closer contacts with the residues in the pocket.  The structure of 
cholecalciferol appears bent when compared to the natural bowl shape of 1,25(OH)2D3 in 
the crystal structure [2].   
Previously, Mizwicki et al. showed that H305F and H305F/H397F caused the wild-
type hVDR antagonist, MK, to act as a superagonist.  Their argument is that MK 
occupies less space in the hVDR ligand binding pocket and therefore does not make the 
necessary contacts with H305 and H397.  This hypothesis is based upon the fact that 
86 
 


































































































































































































































































































































































































when H305 and H397 are mutated to residues bulkier than histidine, the volume of the 
LBP decreases, enhancing the interactions between MK and both H305 and H397, and 
increasing van der Waals contacts with surrounding residues, such as F401 and F422.  
This could then lead to tighter coactivator binding and increased activation [3, 4].   
Based upon the results from Chapters 2 and 3, the idea was developed such that in 
order to obtain maximal activation with cholecalciferol, a combination of a bulky residue 
and a bulky residue with hydrogen bonding potential was needed.  Based on the results 
with H305F/H397Y and the previous findings of Mizwicki et al., a series of single and 
double mutants at the H305 and H397 positions with both phenylalanine and tyrosine 
were created in an effort to determine whether increased sensitivity would also be 
observed with H397F and H397Y, as was observed with H305F and H305Y.  Due to 
H397’s location on the same side of the pocket as H305, a variation in the activation 
profile should be noticed.  The double variants were created in an attempt to determine 
the combination of residues required for maximal activation as well as increased 
sensitivity with cholecalciferol.   
4.2 Phenylalanine and Tyrosine Variants 
4.2.1 Testing Phenylalanine and Tyrosine Variants in Yeast 
Wild-type hVDR was subjected to site-directed mutagenesis in order to create a 
combination of single and double variants with phenylalanine and tyrosine.  The variants 
H397F, H397Y, H305F/H397F, H305Y/H397F, and H305Y/H397Y were created via 
site-directed mutagenesis.  These variants in addition to H305F, H305Y, H305F/H397Y, 
wild-type hVDR, and Gal4 were tested with 1,25(OH)2D3, LCA, and cholecalciferol.  
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Gal4 was used as the positive control, and wild-type hVDR was used as the negative 
control.   
The variants were first tested in chemical complementation with 1,25(OH)2D3 to 
determine whether the mutations would alter the activation profile observed with the 
wild-type ligand, 1,25(OH)2D3.  Chemical complementation links the activation of a 
nuclear receptor by a small molecule to the survival of yeast.  Therefore, if the ligand 
activates the variant, then yeast growth should be observed.  As can be seen in Figure 
4.2A, all variants including wild-type showed ligand-activated growth with 1,25(OH)2D3 
at and EC50 of 5 nM with about 10-fold activation with the exception of  H397F and 
H305F/H397F.  Ligand-activated growth was not observed with H397F.  The double 
variant, H305F/H397F, was observed to be constitutively active (growth is observed in 
the absence of ligand), confirming the hypothesis made by Mizwicki et al.  [3].  Using 
molecular dynamics, a series of calculations showed that H305F/H397F should remain in 
the active conformation in the absence of a ligand, causing a constitutively active 
receptor. Although H305F/H397F was later shown to be ligand-activated by Mizwicki et 
al., these results confirm their original hypothesis [3, 4].  
The variants were tested for growth in yeast with LCA to determine whether a trend 
could be observed relating activation profiles and mutations.  hVDR is hypothesized to 
require a bulky residue at H305 in order to obtain activation with LCA in yeast.  The only 
variants that should display increased sensitivity are H305F, H305Y, H305F/H397Y, 
H305Y/H397F, and H305Y/H397Y due to the presence of a bulky residue at H305.  As 












































































































































































































































































































contained a mutation at H305 displayed ligand-activated growth in response to LCA with 
the exception of H305F/H397F.  H305F, H305Y, H305F/H397Y, H305Y/H397F, and 
H305Y/H397Y display an EC50 of 0.5 µM with an 8-fold activation in adenine selective 
media.  These results are in comparison to wild-type, H397F, and H397Y, which do not 
show ligand-activated growth with LCA in adenine selective media, as well as 
H305F/H397F, which is constitutively active.  
As described in Chapter 3, the double variant, H305F/H397Y, shows ligand-activated 
growth with cholecalciferol at 10 µM in yeast.  The hypothesis is that the combination of 
a bulky residue and a bulky residue with hydrogen bonding potential, as seen with 
phenylalanine and tyrosine, is needed for activation with cholecalciferol in yeast.  When 
the variants were tested with cholecalciferol, only H305F/H397Y and H305Y/H397F 
show ligand-activated growth in adenine selective media displaying an EC50 of 1 µM 
cholecalciferol with a 8-fold activation, the other variants, including wild-type hVDR, 
show no ligand-activated growth.  H305F/H397F was constitutively active (Figure 4.2C).  
These results confirm the hypothesis that a combination of a bulky residue and a bulky 
residue with hydrogen bonding potential is needed at H305 and H397, respectively, in 
order to obtain ligand activation with cholecalciferol in yeast. 
All of the variants display wild-type activation levels with 1,25(OH)2D3, except 
H397F and H397Y, which suggests that hydrogen bonding is not essential at H305.  
However, the results do suggest that H397 is less tolerant to mutations than H305.  Only 
variants containing a mutation at H305 showed increased sensitivity with LCA.  This 
result confirms the hypothesis that bulk is needed at H305 in order to obtain activation 
with LCA.  As for cholecalciferol, only the two variants that contained a combination of 
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a bulky residue and bulky residue with hydrogen bonding potential at H305 and H397, 
H305F/H397Y and H305Y/H397F, displayed ligand-activated growth with 
cholecalciferol, as expected.  This suggests that the presence of histidines in wild-type 
hVDR at 305 and 397 ensures VDR binding and activation in response to 1,25(OH)2D3 
and not cholecalciferol.  This could potentially be due to the strictly regulated production 
of 1,25(OH)2D3.  If wild-type hVDR could slightly bind cholecalciferol, regulation would 
be lost, causing a drastic effect on the regulation of calcium homeostasis, as well as, other 
regulatory pathways [5].  
4.2.2 Testing Phenylalanine and Tyrosine Variants in Mammalian Cells 
To confirm the results that were observed in yeast, the variants were cloned into a 
mammalian expression vector, pCMXGBDhVDR, via site-directed mutagenesis in order 
to be tested in mammalian cell culture.  pCMXGBDhVDR, a mammalian expression 
vector, contains the Gal4 DNA binding domain fused to the hVDR gene under the control 
of a cytomegalovirus promoter.  The variants were tested with all three ligands 
(1,25(OH)2D3, LCA, and cholecalciferol).  The results with 1,25(OH)2D3 were 
confirmed, as all of the variants in addition to wild-type showed activation at an EC50 of 3 
nM except for H305F/H397F, which was constitutively active displaying a fold activation 
of 3 +2 (Table 4.1, Figure 4.3A).  The only observed difference between mammalian 
cells and yeast was regarding H397F, which did not display ligand-activated growth in 
yeast but displays an EC50 of 3 nM in mammalian cells.  This is most likely due to the 
differences between the two systems.  In chemical complementation a specific 
coactivator is introduced into the system, whereas mammalian cells express an array of 
coactivators that can be recruited for transcriptional activation.  Based on the results of 
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Mizwicki et al., hydrogen bonding residues should not be necessary at H305 and H397 to 
achieve activation with 1,25(OH)2D3 [3, 4].  This hypothesis was confirmed by the fact 
that all of the variants, whether containing a phenylalanine or tyrosine, displayed wild-
type activation levels with 1,25(OH)2D3 in mammalian cells (Figure 4.3A). 
The variants were then tested in mammalian cell culture with LCA to determine 
whether the same trends were observed as in yeast.  Only variants with a mutation at 
H305 displayed an increased sensitivity similar to yeast towards LCA in comparison to 
wild-type hVDR (Figure 4.3B).  All site-directed variants containing a mutation at 
position 305 showed activation with LCA, whereas the two single variants containing a 
mutation at position 397, H397F and H397Y, showed no activation with LCA.  Wild-type 
hVDR only showed slight activation at the highest concentration.  An EC50 of 10 µM was 
observed for H305F, H305Y, H305F/H397Y, and H305Y/H397F, with fold activations of 
46 + 22, 78 + 15, 50 + 3, and 47 + 2, respectively.  EC50’s of 50 µM and greater than 100 
µM with fold activations of 69 + 9 and 10 + 5 were observed for H305Y/H397Y and 
wild- type hVDR, respectively (Table 4.1).  H305FH397F was also shown to be 
constitutively active in mammalian cells as well as yeast displaying a 3 + 2 fold 
activation.  Considering these results with LCA, the hypothesis was that a bulky residue 
was needed at H305 to increase sensitivity.  This was confirmed by the fact that only 
variants containing a mutation at H305 (H305F, H305Y, H305F/H397Y, H305Y/H397F, 
and H305Y/H397Y) displayed increased activation with LCA in yeast and mammalian 































































































































































































































































































Table 4.1:  EC50 values and Fold-activations with various ligands in HEK293T cells
Variant Lithocholic Acid Cholecalciferol 1,25 (OH)2D3
wt > 100 µM, 10 + 5 - 3 nM, 82 + 13
H305F 10 µM, 46 + 22 10 µM, 39 + 7 3 nM, 126 + 43
H305Y 10 µM, 78 + 15 10 µM, 70 + 26 3 nM, 92 + 16
H397F - 100 µM, 24 + 5 3 nM, 99 + 23
H397Y - - 3 nM, 81 + 15
H305F/H397F 3 + 2 3 + 2 3 + 2
H305F/H397Y 10 µM, 50 + 3 0.5 µM, 43 + 5 3 nM, 46 + 10
H305Y/H397F 10 µM, 47 + 2 0.5 µM, 42 + 16 3 nM, 52 + 6
H305Y/H397Y 50 µM, 69 + 9 50 µM, 60 + 6 3 nM, 80 + 15
- = no activation observed
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All of the variants display activation with cholecalciferol except for H397F and H397Y.  
However, only H305F/H397Y and H305Y/H397F display maximal activation with 
cholecalciferol.  In mammalian cell culture all of the variants were activated by 
cholecalciferol except H397Y and wild-type hVDR (Figure 4.3C).  An EC50 of 500 nM 
was seen with H305F/H397Y and H305Y/H397F with 43 +5 and 42 + 16 fold 
activations, respectively (Table 4.1).  An EC50 of 10 µM was observed for H305F and 
H305Y as well as 39 + 7 and 70 + 26 fold activations, respectively.  EC50’s of 100 µM 
and 50 µM with fold activations of 24 + 5 and 60 + 6 were observed for H397F and 
H305Y/H397Y, respectively, and H305FH397F was constitutively active.  Activation 
was not seen for wild-type hVDR.  Maximal activation should only be observed with a 
combination of bulky residue and bulky residue with hydrogen bonding potential.  
Although activation was observed with H305F, H305Y, H305Y/H397Y, and H397F in 
mammalian cell culture, maximal activation was only observed with H305F/H397Y and 
H305Y/H397F (EC50 = 0.5 µM).  These results confirm that a bulky residue in 
combination with a bulky residue with hydrogen bonding potential is needed at H305 and 
H397 in order to obtain maximal activation with cholecalciferol. 
4.3 The Role of Volume and Hydrogen Bonding 
Results have shown that a bulky residue is needed at H305 in order to achieve 
increased sensitivity towards LCA.  Additional results have shown that a combination of 
bulky and bulky/hydrogen are needed in order to achieve maximal activation with 
cholecalciferol in yeast.  In order to investigate the limits of volume and polarity that are 
necessary at H305 and H397 with LCA and cholecalciferol, another subset of single and 
double variants was created.  In order to achieve this, residues were chosen that varied in 
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volume, hydrogen bonding potential, and charge.  The residues chosen as substitutions 
were tryptophan, leucine, serine, and lysine.  Tryptophan was chosen because this residue 
has the largest volume (227.8 Å
3
) of all of the amino acids, testing the limit to which 
volume/bulk can be tolerated at those positions [6].  If volume/bulk is required at H305 
for activation with LCA, then H305W should display ligand-activated growth with LCA, 
unless this mutation leads to constitutive activity.  Also, because evidence suggests that 
the removal of hydrogen bonding potential at H305 does not affect activation with 
1,25(OH)2D3, ligand-activated growth should be observed with H305W.  Leucine (166.7 
Å
3
) is slightly larger than histidine (153.2 Å
3
) and therefore, the activation should vary 
with LCA, but should not affect activation with 1,25(OH)2D3.  Serine (89.0 Å
3
) is smaller 
in volume than histidine but provides the potential of a hydrogen bond.  This could lead 
to either an active or inactive receptor, depending on whether the volume/bulk or 
hydrogen bonding takes precedence.  Lysine (168.6 Å
3
) is a charged residue.  Previously, 
results have shown that mutating H305 to a glutamine causes a decreased sensitivity with 
1,25(OH)2D3, leading to Type II Rickets [7]. Therefore, lysine variants should not display 
ligand-activated growth with 1,25(OH)2D3, and is unlikely to be ligand-activated with 
LCA and cholecalciferol as well. 
4.3.1 Testing Variants in Yeast 
The variants were created via site-directed mutagenesis, then tested in yeast with 
1,25(OH)2D3, LCA, and cholecalciferol.  As seen in Figure 4.4, only H305L shows 
ligand-activated growth with 1,25(OH)2D3.  An EC50 of 10 nM with a 14-fold activation, 
which is comparable to wild-type hVDR is observed.   The lack of activation with 
H305W could be due to the bulkiness of this residue, indicating that perhaps a limitation 
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is present in terms of volume.  The H305 single variants were also tested with LCA.  As 
can be seen in Figure 4.4B, all of the variants showed ligand-activated growth 
comparable to wild-type hVDR, with an EC50 of 5 µM and a 3-fold activation, except in 
the case of the H305W and H305K variants.  No ligand-activated growth is observed 
with H305K, which was expected based on previous results with another charged residue, 
H305Q.  As can be seen in orange in Figure 4.4B, H305W displays an 8-fold activation 
with LCA, which demonstrates enhanced activity in comparison to wild-type hVDR and 
the other variants, which was expected due to the bulkiness of this residue.  All of the 
variants were then tested with cholecalciferol and as can be observed in Figure 4.4C, no 
ligand-activated growth is occurs with any of the variants.  These results were expected 
due to the fact that none of the single variants provided the combination of both bulk and 
bulk/hydrogen bonding potential at H305 and H397. 
The H397 single variants were also tested in yeast with the same ligands (Figure 4.5).  
The variants were tested with 1,25(OH)2D3 and ligand-activated growth was only 
observed with H397W and wild-type hVDR at and EC50 of 10 nM 1,25(OH)2D3 with 11-
fold activation (Figure 4.5A).  The variants were then tested with LCA and all of the 
variants showed similar EC50’s to wild-type hVDR of 5 µM LCA and 3-fold activation, 
which was expected due to the hypothesis is H305 is the most important residue for LCA 
ligand activation (Figure 4.5B).  When the variants were tested with cholecalciferol, none 
displayed ligand-activated growth, as was expected (Figure 4.5C). 
The H305/H397 double variants were also tested in yeast (Figure 4.6).  The variants 

































































































































































































































































































































































































































































































































































































































































shows ligand-activated growth.  H305W/H397W displayed an EC50 of 50 nM and 6-fold 
activation with 1,25(OH)2D3 in comparison to an EC50 of 10 nM and 11-fold activation 
with wild-type hVDR.  Therefore, a ten-fold decrease is observed with this double variant 
with 1,25(OH)2D3.  This was not expected because H305F/H397F is constitutively active, 
and H305W/H397W was hypothesized to also be constitutively active due to the fact that 
tryptophan is bulkier than phenylalanine should prevent the ligand from gaining access to 
the pocket.  When other double variants were tested with LCA, none showed ligand-
activated growth (Figure 4.6B).  H305W/H397W seems to display slight growth with 
cholecalciferol with an EC50 of 5 µM and 3-fold activation, most likely due to the 
bulkiness of the two residues.  There is a possibility that because tryptophan is so bulky, 
the introduction of two tryptophans creates novel interactions with cholecalciferol that 
compensates for the lack of hydrogen bonding potential. 
4.3.2 Testing Variants in Mammalian Cells 
Since all of the H305 singles and H305W/H397W showed some growth with either 
LCA or cholecalciferol, each variant was tested in mammalian cell culture.  When the 
single variants were tested at higher concentrations of 1,25(OH)2D3, activation was 
observed with all of the variants.  Wild-type hVDR, H305F, and H305L all display EC50 
of 3 nM, whereas H305S, H305W, and H305K show EC50 of 100 nM with 1,25(OH)2D3 
with fold activations ranging from 126 + 43 for H305F to 44 + 9 for H305W confirming 
that hydrogen bonding is not the predominant factor in ligand activation with 
1,25(OH)2D3 (Figure 4.7A, Table 4.2).  H397 also appears to be less tolerant to mutations 













































































































































































































































































































































 show a 10-fold decrease in sensitivity with 1,25(OH)2D3 suggesting that hVDR prefers 
residues that have the hydrogen bonding potential (histidine or tyrosine) or residues that 
are similar or slightly larger in volume than histidine (leucine and phenylalanine).  
Charged residues, residues that are significantly smaller in volume than histidine, and 
extremely bulky residues do not appear to tolerate 1,25(OH)2D3  as the ligand. 
When the single variants were tested with LCA, activation was observed with 
H305W and wild-type hVDR whereas the other single variants were not ligand-activated 
(Figure 4.7B).  H305W has an EC50 of 30 µM and 14 + 22 fold activation with LCA in 
comparison to 100 µM and 8 + 1 fold activation with wild-type hVDR, which appears to 
confirm the yeast data (Table 4.2).  H305W was the only variant that displayed ligand 
activation with LCA, confirming our hypothesis that bulkiness is required at H305 to 
obtain activation with LCA.  However, H305W has a higher EC50 with LCA than H305F 
and H305Y suggesting that these residues may be the volume at which maximal 
activation occurs; therefore, a residue bulkier than histidine is required for activation with 
LCA.  However, if the residue is too bulky the result is most likely crowding, which 
could lead to a decrease in ligand sensitivity. 
When the variants were tested with cholecalciferol activation was observed with 
H305L displaying an EC50 of 30 µM and 29 + 5 fold activation, which was not observed 
in chemical complementation.  No ligand-activated growth was observed with 
cholecalciferol and H305L in yeast.  This inconsistency may be a result of the coactivator 
differences in the two systems.  A specific coactivator is introduced into yeast, whereas, 
mammalian cells have various coactivators present.  H305L shows the same trend as 






























































































































































































Table 4.2:  EC50 values and Fold-activations with various ligands in HEK293T cells
Variant Lithocholic Acid Cholecalciferol 1,25 (OH)2D3
wt > 100 µM, 8 + 1 - 3 nM, 82 + 13
H305F 10 µM, 46 + 22 10 µM, 39 + 7 3 nM, 126 + 43
H305L - 30 µM, 29 + 5 3 nM, 89 + 16
H305S - - 100 nM, 103 + 20
H305W 30 µM, 14 + 5 - 100 nM, 44 + 9
H305K - - 100 nM, 104 + 10
H305W/H397W - 3 µM, 21 + 6 100 nM, 51 + 15
H305W/H397F 3 µM, 11 + 1 1 µM, 15 + 2 100 nM, 27 + 5
H305L/H397Y - 1 µM, 23 + 2 10 nM, 55 + 7
- = no activation observed
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make other LBP contacts crucial for activation with cholecalciferol.  Activation was also 
observed with H305W/H397W at an EC50 of 3 µM and 21 + 6 fold activation with 
cholecalciferol.   These results suggest that bulkiness plays a more critical role in ligand 
activation at H305 and H397 than hydrogen bonding and electrostatics.  The hypothesis 
was that H305W/H397W would most likely be constitutively active since H305F/H397F 
displays constitutive activity, and tryptophan is a bulkier residue than phenylalanine.  
However, H305W/H397W displays ligand-activated growth, suggesting that the 
interactions of the two tryptophans with the surrounding residues are different that the 
interactions with the two phenylalanines, leading to the different activation profiles. 
4.4 Mixed Double Variants 
Based on the results mentioned above, double variants were created to further test the 
hypotheses that were made.  By combining mutations, a more comprehensive 
understanding of the residues that are necessary at H305 and H397 to achieve activation 
with LCA and cholecalciferol could be achieved.  Therefore, the tryptophan, leucine, 
serine, tyrosine, and phenylalanine residues were tested in combination with each other at 
H305 and H397.   
The variants were created via site-directed mutagenesis and tested in liquid 
quantitation in yeast.  Figure 4.8 shows a subset of the variants that were created.  As can 
be seen in Figure 4.8A, H305W/H397F displays an EC50 of 0.5 µM and 6-fold activation 
with LCA in comparison to an EC50 of 5 µM and 3-fold activation with wild-type hVDR 
and H305F/H397L.   Only two of the variants displayed ligand-activated growth with 
cholecalciferol; H305W/H397F and H305L/H397Y showed EC50’s of 1 µM and 5 µM, 
respectively and 5-fold activation with cholecalciferol (Figure 4.8B).   
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Based on these results, H305W/H397F and H305L/H397Y were tested in 
mammalian cell culture with 1,25(OH)2D3, LCA, and cholecalciferol.  As can be seen in 
Figure 4.9A, both variants display a decreased sensitivity towards 1,25(OH)2D3.  
H305W/H397F and H305L/H397Y display EC50’s of 100 nM and 10 nM with fold 
activations of 27 + 5 and 55 + 7, respectively.  The decrease in activation with 
H305W/H397F was expected due to previous results showing a reduced sensitivity with 
1,25(OH)2D3 in regards to the H305W and H397F single variants.  However, the 
decreased sensitivity with H305L/H397Y was not expected due to the previous results 
that showed wild-type activation levels with both of the single variants, H305L and 
H397Y.  The possibility exists that the combination of the two residues leads to changes 
in the contacts with other residues that affect the sensitivity. 
As observed in yeast, H305W/H397F displays activation with LCA with an EC50 
of 3 µM and 11 +1 fold activation in comparison to 100 µM and 8 + 1 fold activation for 
wild-type hVDR in mammalian cells (Figure 4.9B, Table 4.2).  These results were 
expected due to previous results that showed activation of H305W with LCA.  No ligand 
activation was observed with H305L/H397Y, which was expected due to the lack of 
activation of both single variants with LCA. 
     Both H305W/H397F and H305L/H397Y display activation with cholecalciferol 
with an EC50 of 1µM and 15 + 2 and 23 + 2 fold activations, respectively as can be seen 
in Figure 4.8C (Table 4.2).  These results were expected due to the fact that both the 
H305L single variant and the H305W/H397W double variant display activation with 
cholecalciferol.  Therefore, H305L in combination with H397Y displaying increased 






Figure 4.8: Testing H305 and H397 mixed double variants with 
various ligands in yeast.
A) Lithocholic Acid in histidine selective media with 0.1 mM 3AT,
B) Cholecalciferol in histidine selective media with 0.1 mM 3AT.
Figure 4.8: Testing H305 a 397 mixed double variants with 
various ligands in yeast. A) H305W/H397Y, H305F/H397L, and 
H305W/H397F display ligand-activated growth with lithocholic acid 
in histidine selective media with 0.1 mM 3AT. B) H305W/H397F and 
H305L/H397Y display ligand-activated growth with cholecalciferol in 























































































































































































































H397F maintains bulkiness at both positions and achieves similar activation to the 
H305W/H397W variant with cholecalciferol.  These results confirm that bulkiness is 
more important than hydrogen bonding and electrostatics at these two positions. 
4.5 Summary 
The results of all of the H305 and H397 variants suggest that certain trends can be 
observed with each ligand.  The results suggest that hydrogen bonding is not the most 
important component of ligand activation with 1,25(OH)2D3.  However, H397 seems to 
be less tolerable to mutations than H305 when binding to 1,25(OH)2D3, but hydrophobic 
residues are tolerated.  Activation by LCA appears to require bulkiness at H305 due to 
the fact that each variant that is activated by LCA at lower concentrations than wild-type 
hVDR contains a residue bulkier than histidine at 305.  Combining all of the results with 
cholecalciferol, maximal activation is still observed with a combination of bulky and 
bulky/hydrogen bonding as is observed with H305F/H397Y and H305Y/H397F.  
However, in order to obtain the slightest activation with cholecalciferol, bulky residues , 
such as phenylalanine and tyrosine are needed at both 305 and 397, and specifically at 
H397.  These results suggest that H305 and H397 are important residues in ligand 
binding and activation, given that certain combinations of residues at these positions are 
necessary for activation with the different ligands. 
4.6 Methods and Materials 
4.6.1 Ligands 
Lithocholic acid, cholecalciferol, and 1α,25-dihydroxyvitamin D3 were ordered from 
MP Biomedicals, LLC (Solon, OH), Sigma-Aldrich (St. Louis, MO), and BIOMOL 
(Plymouth Meeting, PA), respectively.  10 mM stocks of lithocholic acid and 
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cholecalciferol and a 13.3 µM stock of 1α,25-dihydroxyvitamin D3 were made with 80% 
ethanol: 20% DMSO as the solvent and stored at 4 °C.  
4.6.2 Site-directed Mutagenesis 
pGBDhVDR was used as the template DNA, site-directed mutagenesis with primers: 
5’-gcgcagcctcaatgaggagCACtccaagcagtatcgatgcctctccttccagcctg-3’ and 5’-
caggctggaaggagaggcatcgatactgcttggaGTGctcctcattgaggctgcgc-3’ for the H397 variants 
and 5’-caagtaccgcgtcagtgacgtcaccaaagccggaCACagcctggagctgattgagcc-3’ and 5’-
ggctcaatcagctccaggctGTGtccggctttggtgacgtcactgacgcggtacttg-3’ for the H305 variants.  
The CAC and GTG were changed to codons for the respective variant.  The PCR 
program used was: 95 ºC for 4 min, 95 ºC for 1 min, 56 ºC for 1 min, 72 ºC for 9 min, 
and 18 cycles. 
4.6.3 Liquid Quantitation Assay 
Variants were tested in liquid quantitation assays in 96-well plates with media lacking 
adenine, leucine, and tryptophan (SC-ALW), with or without LCA, cholecalciferol, or 
1,25(OH)2D3 at varying concentrations (ranging from 0.01 µM - 10 µM for LCA and 
cholecalciferol, 1 nM - 1 µM for 1,25(OH)2D3).  A 4:1 ratio of media (SC-ALW): cells 
(yeast resuspended in water) were aliquoted into 96-well plates.  Plates were incubated at 
30°C, with shaking at 170 rpm.  Optical density (OD) readings at 630 nm were recorded 
at 0, 24, and 48 hours as a measure of growth density.  
4.6.4 Mammalian Cell Culture 
HEK293T cells (ATCC, USA) were transfected with the plasmids of interest.  These 
plasmids contain the Gal4DBD (GBD) fused to the corresponding VDR ligand binding 
domain (GBD:LBD fusion under the control of a cytomegalovirus (CMV) promoter).  
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The reporter plasmids were p17*4TATAluc, containing the Renilla luciferase gene under 
the control of four Gal4 response elements located upstream from a minimal thymidine 
kinase promoter, and pCMXβgal, a plasmid containing the β-galactosidase gene under 
the control of the mammalian CMV promoter.  Lipofectamine 2000 (Invitrogen, USA) 
served as the cationic lipid and transfection experimental details are described in Taylor 
et al. [8].  The ligands were added to the wells at various concentrations ((0.01 µM- 100 
µM) LCA and (0.01 µM- 32 µM) cholecalciferol).  Cells were harvested and analyzed for 
luciferase and β-galactosidase activity.  All data points represent the average of triplicate 
experiments normalized against β-galactosidase activity.  Error bars represent the 
standard deviation calculated using standard deviation: σ = Square root (Σ[(X-µ)
2
]/N).  
Fold activation was calculated by dividing the value at maximal activation by the value at 
the no ligand data point.   
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In order to further study wild-type hVDR and the hVDR variants, they needed to be 
expressed and purified in bacteria using a maltose binding protein fusion.  The maltose 
binding protein is used throughout protein expression to allow for the protein of interest 
to be expressed in the soluble fraction of protein within the bacteria.  Although the exact 
mechanism by which the maltose binding protein aids in solubility is unknown, the 
protein is hypothesized to act as a chaperone in order to move the protein of interest into 
the soluble fraction [1]. 
Once wild-type hVDR and the hVDR variants are expressed and purified various 
studies can be conducted on the pure proteins.  Ligand binding studies can be performed 
to determine the binding affinity of various ligands.  Also, an attempt can be made to 
crystallize the variants with the various liagnds of interest to allow for a more 
comprehensive structural analysis of the protein-ligand interactions. 
5.2 Expression and Purification of Proteins 
5.2.1 Cloning VDR Ligand Binding Domains into a Bacterial Expression Vector 
In order to perform binding studies on wild-type hVDR and the variants discussed in 
Chapters 3 and 4, the proteins were cloned into pMalRXR, a bacterial expression vector.  
The pMal vector contains the gene for the maltose binding protein (MBP) fused to the 
RXRLBD.  The MBP increases the solubility of proteins expressed in E.coli, which is 
necessary for protein purification.  The mechanism by which MBP aids in solubility is 
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not well understood, but several hypotheses indicate that the MBP could act as a 
chaperone as well as engage in preventing aggregation [1]. 
The wild-type hVDR ligand binding domain (LBD) and variants: H305FLBD, 
H305F/H397YLBD, and H305FH397FLBD were cloned out of pGBDhVDR with 
primers containing EcoRI and SpeI restriction sites.  pMalRXR was then digested with 
EcoRI and SpeI , which removed the RXR gene and ligated wild-type hVDR and the 
variants into the vector.  These plasmids were confirmed by sequencing. 
5.2.2 Expression and Purification of MBP Fusion and TEV Protease 
Once the bacterial expression vectors were created, the proteins were over-expressed 
and purified using an amylose resin column.  MBP generally binds to maltose, but can 
also bind to amylose [2].  Therefore, when the over expressed protein is applied to the 
resin, the fusion protein will bind to the amylose resin.  The fusion protein consists of the 
MBP fused to the VDRLBD.  The two proteins are separated by a histidine-tag and a 
TEV protease cleavage site (Figure 5.1).   
Throughout the expression and purification process, samples from each step are 
collected for further use.  These samples are run on a 12 % SDS-PAGE gel to determine 
the success of protein expression and purification.  As can be seen in Figure 5.2, lanes 2 
and 3 represent the bacterial expression.  A bright band is observed at approximately 80 
kD in lane 2, which represents the over expression of the fusion protein.  The insoluble 
fraction in lane 3 also indicates the presence of the fusion protein, which is most likely 
due to incomplete cell lysis during the expression.  Lanes 4-8 represent the purification, 

























Figure 5.2: Diagram of fusion protein plasmid 
construction. 




1 2 3 4 5 6 7 8
~ 80 kD
Figure 5.3: Expression and Purification of MBP-VDRLBD fusion protein.
The fusion protein is about 80 kD. Lane 1= Protein marker, Lane 2= soluble 
fraction, Lane 3= insoluble fraction, Lane 4= post resin, Lanes 5-7= resin 












Figure 5.2: Expression and Purification of MBP-VDRLBD fusion 
protein. The fusion protein is about 80 kD. Lane 1= Protein marker, 
Lane 2= soluble fraction, Lane 3= insolubl  fraction, Lane 4= post 




 protein of the MBP and VDR is observed in the post resin, which indicates unbound 
protein within the resin, implying more resin might be needed to accommodate the 
amount of protein present in the soluble fraction.  The purified fusion protein is observed 
at approximately 80 kD (lane 8), yielding 2-3 mg/mL of purified fusion protein.  Binding 
studies require pure VDRLBD; the MBP must be cleaved from the VDR. 
 The tobacco etch virus (TEV) protease functions like a serine protease, with the 
exception that serine in the active site replaced by a cysteine in TEV.  The TEV protease 
cleaves via peptide hydrolysis at a specific sequence, EXXYXQ(G/S), where cleavage 
occurs between the glutamate and glycine or serine [3].  TEV protease was expressed and 
purified using a metal affinity column, due to the histidine-tag present at the N-terminal 
of this protein.  The metal affinity column has space requirements that only allow 
proteins with adjacent histidines to bind to the resin.  Expressed and purified TEV 
protease should display a band around 27 kD.  As can be seen in Figure 5.3, TEV 
protease can be observed in the soluble fraction in lane 2 at around 27 kD.  However, 
residual protease is present in the insoluble fraction (lane 3) in comparison to the soluble 
fraction, indicating incomplete cell lysis.  Purified TEV protease is seen at 27 kD (lane 7) 
with a concentration of approximately 1 mg/mL.  
5.2.3 Fusion Protein Cleavage and Purification 
Once the TEV protease was purified, the protease was used to cleave the fusion of 
MBP and the wild-type VDR or the VDR variants.  The TEV protease was added to the 
fusion protein at a ratio of 1 mg of TEV protease for every 100 mg of the fusion protein 
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~ 27 kD
Figure 5.4: Expression and Purification of TEV protease.
TEV protease should be about 27 kD. Lane 1= protein marker, 
Lane 2= soluble fraction, Lane 3= insoluble fraction, Lane 4= 













Figure 5.3: Expression and Purification of TEV protease.  TEV 
protease should be about 27 kD. Lane 1= protein marker, Lane 2= soluble 
fraction, Lane 3= insoluble fraction, Lane 4= post resin, Lanes 5 and 6= 
resin washes, Lane 7 = purified TEV protease  
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however cleavage was performed at 4 °C to maintain the receptor’s stability, and the time 
for cleavage was extended to 24 hours.  After the 24 hour digest, the cleaved sample was 
run on a metal affinity column to purify the VDRLBD’s, eliminating any remnants of the 
MBP and TEV, since both also contain His-tags. 
As can be observed in Figure 5.4, the band at 80 kD observed in lane 2 shows that the 
protein was cleaved but that the cleavage was incomplete, indicating the presence of 
fusion protein.  Lane 3 shows the flow-through of the cleavage, with pure VDRLBD at 
35 kD along with residual fusion still present at 80 kD.  Lane 4 shows that MBP is 
present at 37 kD in the column elution.  Lanes 5-7 show the same results but with the 
H305F variant.  The purified LBDs fluctuated in concentration from 0.8 to1.5 mg/mL 
after cleavage and purification.  Wild-type hVDR and variants have been expressed and 
purified successfully, but contain remnants of the fusion protein, preventing a higher 
yield of the pure protein. 
 
5.3 Summary and Future Work 
Wild-type hVDR and hVDR variant proteins were able to be obtained via expression 
and purification.  However, pure protein could not be isolated due to the presence of 
fusion protein in the sample after the cleavage occurred.  Therefore, optimization of the 
TEV protease expression and purification is needed to ensure consistent activity of this 
protease.  Also, the cleavage time and ratio of TEV protease to fusion protein need to be 
further investigated.  Once pure protein can be isolated, further studies can be performed 












Figure 5.5:  Purification of Cleaved Fusion Protein. The fusion protein is about 80 kD.
However, the Maltose binding protein and the VDRLBD are about 37 and 35 kD, respectively. 
Lane 1= protein marker, Lane 2= wthVDR cleaved, Lane 3= pure VDRLBD, Lane 4= MBP 












Figure 5.4:  Purification of Cleaved Fusion Protein.  The fusion protein is 
about 80 kD.  However, the Maltose binding protein and the VDRLBD are 
about 37 and 35 kD, respectively. Lane 1= protein marker, Lane 2= wthVDR 
cleaved, Lane 3= pure VDRLBD, Lane 4= MBP elution, and Lanes 5-7 




5.4 Methods and Materials 
5.4.1 Ligands 
       Lithocholic acid, cholecalciferol, and 1α,25-dihydroxyvitamin D3 were ordered from 
MP Biomedicals, LLC (Solon, OH), Sigma (St. Louis, MO), and BIOMOL (Plymouth 
Meeting, PA), respectively.  10 mM stocks of lithocholic acid and cholecalciferol and a 
13.3 µM stock of 1α,25-dihydroxyvitamin D3 were made with 80% ethanol: 20% DMSO 
and stored at 4 °C. 
5.4.2 Cloning VDRLBD’s into pMalRXR 
The wild-type hVDRLBD and hVDR variant LBD’s were amplified with PCR using 
the following primers: 5’- ccg gaattc gacagtctgcggcccacgc-3’ and 5’- gg actagt 
tcaggagatctcattgccaaaca-3’. The underlined sequences denote EcoRI and SpeI restriction 
sites, respectively.  pMalRXR was digested with the two restriction enzymes, removing 
the RXRLBD from the plasmid.  The amplified VDRLBD’s were then ligated into the 
linearized pMal plasmid, creating pMalwthVDRLBD, pMalH305FLBD, 
pMalH305F/H397YLBD, and pMalH305F/H397FLBD.  The plasmids were confirmed 
by sequencing (Operon, USA). 
5.4.3 Expression and Purification of MBP-VDR LBD Fusions 
The VDRLBD’s were overexpressed in E.coli BL21D3 cells.  The cells were grown 
to an OD of approximately 0.60 at room temperature and 300 rpm, then induced with 
0.300 mM IPTG.  The induction was performed at room temperature for 16 hours, while 
shaking at 300 rpm.  The overnight cultures were pelleted and lysed to collect the soluble 
fraction for purification.  The purification was performed with an amylose resin affinity 
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column (New England Biolabs, MA), and dialysed overnight.  The protein was then run 
on a 12 % SDS-Page gel and protein concentrations were determined by Bradford assay. 
The maltose wash buffer was prepared as follows: 200 mM NaCl, 10 mM Na2PO4, 10 
mM K2PO4, 1 mM EDTA, and 0.1 mM maltose.  The maltose elution buffer was 
prepared in the same manner as the wash buffer with the exception of the maltose 
concentration.  The elution buffer had a maltose concentration of 20 mM.  The dialysis 
buffer was prepared as follows: 150 mM NaCl, 80 mM Tris-HCl pH 7.6, and 35 % 
glycerol. 
5.4.4 TEV Protease Expression and Purification 
TEV protease was overexpressed in E.coli BL21-RIL D3 cells.  The cells were grown 
to an OD of about 0.60 at 37 °C and 300 rpm and then induced with 1 mM IPTG.  The 
induction was performed for 4 hours at 30 °C and 300 rpm.  After induction the cells 
were pelleted and lysed and the soluble fraction used for purification.  TEV was purified 
using a metal affinity column.  The purified protein was run on a 12% SDS-PAGE gel 
and the concentration was determined by Bradford assay. 
The TEV protease wash buffer was prepared as follows: 50 mM Na2PO4, 50 mM 
K2PO4, 100 mM NaCl, 35 % glycerol, and 25 mM imidazole.  The TEV protease elution 
buffer was prepared the same way as the wash buffer except for a differing concentration 
of imidazole.  The imidazole concentration of the elution buffer was 500 mM. 
5.4.5 Cleaving and Purifying the Fusion Protein 
TEV protease was added to the dialysed fusion protein in a ratio of 1 mg of TEV 
protease for every 100 mg of fusion protein.  The sample was then mixed for 24 hours at 
4 °C.  The sample was then run through a metal affinity column and the flow through was 
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collected (pure VDRLBD).  The column was washed with TEV protease elution buffer to 
collect the cleaved MBP.  The protein was then run on a 12 % SDS-PAGE gel and the 
concentration determined by Bradford assay. 
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Chemical complementation is a genetic selection system which links the survival of 
yeast to the function of a nuclear receptor and a small molecule [1-4].  This versatile 
system can be used for a number of applications, ranging from drug discovery to protein 
and enzyme engineering [2, 3].  The ability to employ a genetic selection system to 
evaluate a library of engineered enzymes for novel activity is an extremely useful tool.  
This method could facilitate the creation of novel small molecules biosynthetically, as an 
alternative to synthetic methods.  For example, a number of antibiotics, such as oxacillin 
and cloxacillin, are currently limited to synthetic production, potentially leading to 
environmental and economic concerns, such as waste production.  Thus, chemical 
complementation is a tool for biocatalysis, where the product of catalysis is linked to the 
survival of yeast, hence enzyme-activated growth [5-7].   
In order to use chemical complementation for enzyme engineering and enzyme-
activated growth, several components must be present.  First, the system must have a 
target product.  The second component is an engineered nuclear receptor that is capable 
of bind and activating in response to the target product but not the substrate.  Finally, a 
library of engineered enzymes is required.  If an engineered enzyme from the library is 
capable of producing the desired product, then the product will bind to the nuclear 
receptor and growth will be observed (Figure 6.1).  To determine whether the survival of 
yeast can be linked to enzyme-activated growth, as a proof of principle, a known 
enzymatic pathway in the vitamin D biosynthesis pathway was used. 
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 The biosynthetic pathway for 1,25(OH)2D3 includes a three step process.  First, 7-
dehydrocholesterol in the skin is converted to cholecalciferol after exposure to UVB (315 
nm- 280 nm) by the opening of the ring system.  Next, cholecalciferol is hydroxylated at 
the 25-carbon by 25-hydroxylase, an enzyme in the liver, to create the product 25-
hydroxyvitaminD3.  25-hydroxyvitaminD3 is finally hydroxylated at the 1α-carbon by 1α-
hydroxylase, an enzyme in the kidneys, to create 1α,25-dihydroxyvitaminD3, which is the 
biologically active compound (Figure 6.2) [8, 9]. 
     Two different pathways of 1α,25-dihydroxyvitaminD3 biosynthesis were tested in 
chemical complementation for enzyme activated growth.  First, the conversion of 7-
dehydrocholesterol into cholecalciferol using ultra-violet rays (UV) was investigated.  As 
seen in Figure 6.1, if the 7-dehydrocholesterol (substrate) is converted by UV to 
cholecalciferol (product), the cholecalciferol should be able to bind and activate the 
hVDR variant, H305F/H397Y (engineered NR), allowing yeast to survive.  The second 
targeted pathway, the conversion of the substrate cholecalciferol into 25-
hydroxyvitaminD3 by the enzyme 25-hydroxylase was investigated.  If cholecalciferol 
(substrate) is converted into 25-hydroxyvitaminD3 (product), then this molecule should 
be able to bind the wild-type hVDR (NR) and yeast should survive as a result of the 
enzymatic reaction. 
6.2 Converting 7-dehydrocholesterol into Cholecalciferol 
6.2.1 Testing hVDR and Variants with 7-dehydrocholesterol 
The first step of the biosynthetic pathway is the conversion of 7-dehydrocholesterol into 
cholecalciferol.  Exposing 7-dehydrocholesterol to ultraviolet rays (UV) causes the 



































































































































































































































system, if the 7-dehydrocholesterol is converted into cholecalciferol, ligand-activated 
growth should be observed with H305F/H397Y, which has been shown to be activated by 
cholecalciferol, whereas wild-type hVDR should not display growth. 
Before testing the conversion of 7-dehydrocholesterol to cholecalciferol, wild-type 
hVDR and H305F/H397Y were tested with 7-dehydrocholesterol in yeast to confirm that 
this ligand, which serves as the substrate (Figure 6.1) does not activate wild-type hVDR 
or H305F/H397Y.  Wild-type hVDR , H305F/H397Y, and Gal4 (ligand-independent 
control) were tested in yeast with 7-dehydrocholesterol and cholecalciferol.  As shown in 
Figure 6.3A, wild-type hVDR and H305F/H397Y did not display activation in response 
to 7-dehydrocholesterol.  Gal4 shows growth independent of ligand.  As a confirmation, 
wild-type hVDR is not activated by cholecalciferol, whereas H305F/H397Y shows 
ligand-activation at an EC50 of 5 µM and a 7-fold activation with cholecalciferol in 
adenine selective media (Figure 6.3B).  Based upon these results, there should be no 
background growth from 7-dehydrocholesterol when testing for conversion to 
cholecalciferol. 
6.2.2 Using UV to Convert 7-dehydrocholesterol into Cholecalciferol 
6.2.2.1 Experimental Set-up 
Each plasmid was transformed into yeast along with pGAD10BAACTR: Gal4, wild-
type hVDR, H305F, H305Y, and H305F/H397Y.  Wild-type hVDR, H305F, and H305Y 
were used as negative controls, due to their lack of activation with cholecalciferol.  
Therefore, growth should not be observed on the 7-dehydrocholesterol plates or the 
cholecalciferol plates.  Gal4 was again used as the positive control, and should grow on 






Figure 6.3: Testing 7-dehydrocholesterol and cholecalciferol in yeast.




activated growth.  If 7-dehydrocholesterol (substrate) is converted into cholecalciferol 
(product) then yeast containing H305F/H397Y (engineered NR) should grow on the 7-
dehydrocholesterol plates that are exposed to UV (represents enzyme). 
Yeast were streaked onto non-selective plates (-LW), adenine selective plates without 
ligand (-ALW), and adenine selective plates with 10
-5
 M 7-dehydrocholesterol or 10
-5
 M 
cholecalciferol, as well as yeast rich media (YPD) plates.  PJ694A, the yeast strain 
lacking any NR or enzyme, was used as a negative control and should only grow on YPD 
plates.  Gal4, the positive control, should grow on all plates, whereas, wild-type hVDR, 
H305F, and H305Y should show growth on the –LW and YPD plates.  H305F/H397Y 
and H305F/F406S, another variant capable of activating in response to cholecalciferol, 
should grow on –LW, YPD, and cholecalciferol plates.  If 10
-5
 M 7-dehydrocholesterol is 
converted to at least 10
-5
 M cholecalciferol, then H305F/H397Y and H305F/F406S 
should grow on the UV-exposed 7-dehydrocholesterol plates. 
6.2.2.2 Experimental Results 
The plasmids were streaked onto two of each plate; one that was exposed to UV at 
302 nM and one that was not exposed to UV.  The UV plates were exposed to UV for 5 
minutes.  After the exposure, yeast cells containing the NR:GBD fusion and the 
coactivator:GAD fusion, were streaked onto these plates.  The plates were incubated at 
30 °C for 3 days.  As shown in Figure 6.4, all sectors of the –LW plates display yeast 
growth except for the PJ694A sector as expected.  The YPD plates displayed growth in 
all sectors as expected.  Only the Gal4 sector of the adenine selective plate lacking ligand 
displayed growth as expected.  Growth was observed on the cholecalciferol plates in the 
























Figure 6.4: 5 minute UV exposure streaking results. 
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on the 7-dehydrocholesterol plates, except for the sector containing Gal4.  This indicates 
that the conversion was not efficient enough for ligand binding and activation with the 
H305F/H397Y and H305F/F406S variants (Figure 6.4). 
To explore whether the efficiency of the conversion of 7-dehydrocholesterol to 
cholecalciferol was the issue, the UV exposure time was increased to 30 minutes, and as 
can be seen in Figure 6.5, the increase in exposure time did not affect the results.  The 
sector of the plate containing Gal4 displayed growth on all of the plates.  However, Gal4, 
H305F/H397Y, and H305F/F406S were the only sectors where growth was observed on 
the cholecalciferol plates, as expected.  As observed with 5 minute exposure, no colonies 
grew on the 7-dehydrocholesterol plates, except for the sector containing Gal4.  Data has 
shown that H305F/H397Y is activated by 10
-5
 M cholecalciferol, therefore all of the 7-
dehydrocholesterol would need to be converted in order to achieve ligand activation.  
Accordingly, the decision was made to increase the 7-dehydrocholesterol concentration 
to 10
-3
 M.   
A new concentration of 7-dehydrocholesterol of 10
-3
 M was added to the plates.  The 
streaking was repeated with the same plates, controls, and variants as stated above.  
Plates were exposed to UV for 30 minutes and then the yeast were streaked and incubated 
at 30 °C for 3 days.  As shown in Figure 6.6, no growth was observed on the plates 
containing 7-dehydrocholesterol.  The sector containing Gal4 should have grown on the 
7-dehydrocholesterol plates; however, no growth was observed (Figure 6.6 E).  This was 
most likely due to the precipitation of the 7-dehydrocholesterol causing a detrimental 
change in the media for the plates.  Therefore, because the higher concentration of 7-




























reaction in the biosynthetic pathway. 
6.3 Converting Cholecalciferol to 25-hydroxyvitaminD3 
6.3.1 Introduction 
25-hydroxylase (CYP2R1) is a cytochrome P450 enzyme comprised of 501 amino acids.  
CYP2R1 is located in the liver and responsible for converting cholecalciferol into 25-
hydroxyvitaminD3 [8, 10-12].  This enzyme has been shown to have a kcat of 0.97 + 0.05 
min
-1
 as well as a Km of 0.45 + 0.16 µM with cholecalciferol as the substrate in yeast, 
which implies that the turnover rate for this enzyme is fairly slow [12].  
As can be seen in Figure 6.7, if 25-hydroxylase (enzyme) can convert cholecalciferol 
(substrate) into 25-hydroxyvitaminD3 (product), then the 25-hydroxyvitaminD3 should 
bind and activate wild-type hVDR, inducing yeast growth in adenine selective media.  
The ability to use this step in the biosynthetic pathway is due to the fact that wild-type 
hVDR is not activated by cholecalciferol; therefore, no ligand activated growth will be 
observed with wild-type hVDR unless the cholecalciferol has been converted into 25-
hydroxyvitaminD3. 
6.3.2 Cloning 25-hydroxylase from cDNA 
25-hydroxylase is involved in the second step of the 1,25(OH)2D3 biosynthetic 
pathway, which takes place in the liver.  The 25-hydroxylase was cloned out of liver 
cDNA, due to the over expression of this enzyme in the liver.  The gene was isolated and 
amplified from liver cDNA via PCR and cloned into a yeast over expression plasmid, 
pUGPD, which contains a uracil selection marker and a GPD promoter.  The resulting 





























6.3.3 Testing hVDR with 25-hydroxyvitaminD3 
        25-hydroxyvitaminD3 is known to activate wild-type hVDR in mammalian cell 
culture.  However, the ability of wild-type hVDR to be activated by this ligand in yeast 
had not been confirmed.  In order for enzyme-activated growth to be observed, wild-type 
hVDR was tested for activation with 25-hydroxyvitaminD3 in chemical complementation.  
Gal4 was used as the ligand-independent control.  As can be seen in Figure 6.9, ligand-
activated growth is observed with both wild-type hVDR and H305F/H397Y at an EC50 of 
1 µM and 9-fold activation with 25-dihydroxyvitaminD3.  This shows that if 
cholecalciferol is converted into 25- hydroxyvitaminD3 in sufficient amounts, ligand-
activated growth should be observed with wild-type hVDR. 
6.3.4 Experimental Design 
The yeast strain BAPJ694A, which contains a URA3 selection marker in addition to 
ADE2 and HIS3, was used for this set of experiments. A series of plasmids was 
transformed into this yeast strain.  Gal4 (pGBT9Gal4), wild-type hVDR (pGBDhVDR) 
with coactivator, H305F/H397Y (pGBDH305F/H397Y) with ACTR, and 25-hydroxylase 
(pUGPD25-hydroxylase) were transformed into yeast on non-selective plates, selecting 
for the plasmids.  Wild-type hVDR and H305F/H397Y were transformed with and 
without 25-hydroxylase.  The plasmids were then tested in liquid quantitation in adenine 
selective media (-AULW) with varying concentration of cholecalciferol (100 nM – 33.3 
µM) to test for conversion to 25-hydroxyvitamin D3.  Gal4 was expected to display yeast 
growth, independent of ligand.  Wild-type hVDR and ACTR, and 25-hydroxylase were 








































































































































Figure 6.8: Gel of 25-hydroxylase PCR with Sequencing 
Primers. 1= Lambda DNA protein ladder, 2 and 3= 25-




H305F/H397Y and ACTR, as well as H305F/H397Y, ACTR, and 25-hydroxylase should 
display ligand-activated growth at 10 µM cholecalciferol in yeast.  Wild-type hVDR, 
ACTR, and 25- hydroxylase should only display yeast growth upon the conversion of 
cholecalciferol to 25-hydroxyvitamin D3 by 25-hydroxylase.  The yeast were originally 
incubated for 48 hours and the results can be seen in Figure 6.10.  At 48 hours no ligand 
activated growth is observed with the wild-type hVDR construct containing 25-
hydroxylase.  Ligand-activated growth was observed for both H305F/H397Y constructs.  
However, as can be seen in Figure 6.10, the H305F/H397Y construct that contains 25-
hydroxylase shows ligand-activated growth with an EC50 of 5 µM and 8-fold activation 
with cholecalciferol, whereas H305F/H397Y without 25-hydroxylase displays an EC50 of 
1 µM and 8-fold activation.   
Considering these results and the slow enzyme turnover for 25-hydroxylase enzyme, 
the experiment was repeated but was incubated for 96 hours.  The incubation time was 
increased in an effort to allow the enzyme more time for conversion.  These results can 
be seen in Figure 6.11.  As shown at 48 hours, the wild-type hVDR construct with 25-
hydroxylase does not display ligand activated growth.  The main difference is observed 
between the two H305F/H397Y constructs.  The construct without 25-hydroxylase is 
constitutively active after 96 hours.  However, the construct containing 25-hydroxylase is 
ligand-activated with an EC50 of 5 µM and a 7-fold activation with cholecalciferol.  
These results suggest that the presence of the 25-hydroxylase in the yeast is having some 
effect on the ligand activation of the receptor, and most likely some amount of 





Figure 6.9: Testing wild-type hVDR and H305F/H397Y 
with 25-hydroxyvitaminD3.





6.3.5 Extraction of Yeast Lysate 
      Based on the differences observed between the constructs with and without the 25-
hydroxylase, additional information was needed regarding the effect the 25-hydroxylase 
has in yeast.  To determine whether the conversion of cholecalciferol into 25-
hydroxyvitaminD3 via 25-hydroxylase, was occurring, a liquid quantitation assay was 
performed for 96 hours, and the yeast were lysed and analyzed via HPLC to determine 
the presence of 25-dihydroxyvitaminD3.  The organic compound was extracted from the 
yeast lysate, based on a protocol from Shinkyo et al. [12].  This protocol uses a 
chloroform extraction, in which an organic solution was used to allow the compounds to 
preferentially migrate into the desired fraction.  After the extraction, HPLC experiments 
were performed to determine whether the reaction was taking place.  
6.3.6 HPLC Results   
High-performance liquid chromatography (HPLC) is a technique used to separate a 
mixture of compounds into the individual components of the mixture. Mixtures are 
placed onto a column and pushed through the column by a mobile phase (i.e. 
acetonitrile).  The detector assigns retention times specific to each compound, serving as 
a method of identification. 
HPLC was performed on the cell lysate to determine if any of the cholecalciferol was 
being converted into 25-hydroxyvitaminD3.  As can be seen in Figure 6.12, the green line 
represents 33.3 µM cholecalciferol, and the peak for cholecalciferol can be observed 
around 35 minutes.  The navy blue line represents 33.3 µM 25-hydroxyvitaminD3 with a 





Figure 6.10: 25-hydroxylase Enzyme-activated Growth in Yeast at 48 hours.









visualized in Figure 6.12.  There were two negative controls, indicating that only the 
nuclear receptor and coactivator were present in those yeast and therefore none of the 
cholecalciferol should have been converted.  The black line and blue line represent wild-
type hVDR and H305F/H397Y, respectively.  As can be seen in Figure 6.12, the peak at 
35 minutes that should represent cholecalciferol, is not observed in the controls.  This 
implies that cholecalciferol is breaking down over the course of the 96-hour experiment.  
The two positive controls, which contain 25-hydroxylase in addition to the nuclear 
receptor and coactivator, are shown in pink and maroon.  Neither a cholecalciferol peak 
and/or a 25- hydroxyvitaminD3 peak is observed.  This is most likely a consequence of 
the breakdown of the cholecalciferol and, therefore, enzyme-activated growth cannot be 
observed due to insufficient production of 25-hydroxyvitaminD3. 
Sequencing of the pUGPD25-hydroxylase plasmid was never confirmed, lacking 
confirmation of 25-hydroxylase present in the system.  Despite the lack of sequencing, 
the presence of the enzyme in the chemical complementation does cause some effect, as 
can be seen in Figure 6.11.  Confirmation of the presence of the correct enzyme will 
allow for that variable to be eliminated.  Due to the lack of sequencing and HPLC data, 
further studies must be conducted to determine whether the enzyme is fully functional in 
yeast. 
6.4 Summary 
Based on the results seen in Figure 6.11, there is a difference in activation profiles 
between the nuclear receptor without 25-hydroxylase and the nuclear receptor with 25-
hydroxylase.  An assumption can be made that the 25-hydroxylase is having some type of 


































































































































































































cholecalciferol into 25-hydroxyvitaminD3, no conversion was observed due to the 
breakdown of the cholecalciferol over the course of the experiment. 
6.5 Methods and Materials 
6.5.1 Liquid Quantitation Assays 
Plasmids were tested in liquid quantitation assays in 96-well plates with media 
lacking adenine, leucine, and tryptophan (SC-ALW), with or without 7-
dehydrocholesterol, cholecalciferol, and 25-hydroxyvitaminD3 at concentrations ranging 
from 0.01 µM - 10 µM.  A 4:1 ratio of media (SC-ALW): cells (yeast resuspended in 
water) were aliquoted into 96-well plates.  Plates were incubated at 30°C, with shaking at 
170 rpm.  Optical density (OD) readings at 630 nm were recorded at 0, 24, and 48 hours 
as a measure of growth density. 
6.5.2 Streaking for 7-dehydrocholesterol Testing 
Yeast plates were made with or without 7-dehydrocholesterol and cholecalciferol.  
The plates that were made were SC-LW, SC-ALW without ligand, SC-ALW with 7-
dehydrocholesterol or cholecalciferol, and YPD plates.  Plates were exposed to ultraviolet 
rays at 302 nm for 5 minutes or 30 minutes.  The yeast were then streaked onto the plates 
and incubated at 30 °C for 2 days. 
6.5.3 Cloning 25-hydroxylase from cDNA 
The 25-hydroxylase gene (CYP2R1) was cloned from human liver cDNA with PCR 
using the following primers: 5’- aaggaaaaaa gcggccgc atgtggaagctttggagag-3’ and 5’- tcc 
ccgcgg tcagcgtctttcagcac-3’. The underlined sequences denote NotI and SacII restriction 
sites, respectively. The 25-hydroxylase gene and yeast expression vector (pUGPD), were 
digested, ligated, and transformed into Z-competent XL-1 Blue E.coli cells (Zymo, USA).  
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Fusing the 25-hydroxylase to the Gal response elements created the pUGPD25-
hydroxylase plasmid, which contains a uracil marker.  
6.5.4 Testing Conversion of Cholecalciferol in Liquid Quantitation 
The following plasmids were tested in liquid quantitation with cholecalciferol: 
pGBT9, containing Gal4, pGBDhVDR and ACTR and25-hydroxylase, 
pGBDH305F/H397Y and ACTR and 25-hydroxylase, pGBDhVDR and ACTR, 
pGBDH305F/H397Y and ACTR, and pUGPD25-hydroxylase.  Plasmids were tested in 
liquid quantitation assays in 96-well plates with media lacking adenine, leucine, uracil, 
and tryptophan (SC-AULW), with or without cholecalciferol at concentrations ranging 
from 0.001 µM - 33 µM.   
6.5.5 Lysing Yeast 
The 96-well plates were centrifuged at 1500 rpm for 15 minutes and the supernatant 
was removed.  Lyticase (10 mg/mL) was added to the plates and the pellets were 
resuspended.  The plates were then incubated for 30 minutes at 37 °C.  Triton (0.1% v/v) 
was added to the plates and incubated at room temperature for 10 minutes.  The plates 
were then centrifuged at 1500 rpm for 15 minutes.  The supernatant was transferred to a 
new 96-well plate. 
6.5.6 Extraction and HPLC 
The supernatant for each sample was extracted with four volumes of 
chloroform/methanol (3:1 v/v).  The organic phase was recovered by evaporating the 
chloroform/methanol off of the sample.  The residue was dissolved in acetonitrile and 
applied to the HPLC.  HPLC was performed on a YMC-Pack ODS-AM column (4.6 x 
300 mm).  A linear gradient of 70-100% acetonitrile for 15 minutes followed by 100% 
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acetonitrile for 25 minutes was the mobile phase.  The column temperature was 
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